<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fluconazole: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fluconazole: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fluconazole: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8450" href="/d/html/8450.html" rel="external">see "Fluconazole: Drug information"</a> and <a class="drug drug_patient" data-topicid="12475" href="/d/html/12475.html" rel="external">see "Fluconazole: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F171677"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Diflucan</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866909"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Fluconazole;</li>
<li>APO-Fluconazole;</li>
<li>Diflucan;</li>
<li>Fluconazole SDZ;</li>
<li>MYLAN-Fluconazole;</li>
<li>PMS-Fluconazole;</li>
<li>PRO-Fluconazole;</li>
<li>TARO-Fluconazole;</li>
<li>TEVA-Fluconazole</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1047385"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antifungal Agent, Systemic</span></li></ul></div>
<div class="block don drugH1Div" id="F53462453"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing, susceptible infection</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2'])">Ref</a></span>): Preterm and term neonates:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis:</i> IV, Oral: 3 to 6 mg/kg/dose twice <b>weekly</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i> IV, Oral: Initial: 25 mg/kg on day 1, followed by 12 mg/kg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, prophylaxis:</b> Limited data available; optimal dose uncertain.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Early prophylaxis (</i>
<i>initiation in the first 5 days of life): </i>
<b>Note:</b> Recommended for use in NICUs with high rates (&gt;10%) of invasive candidiasis.</p>
<p style="text-indent:-2em;margin-left:6em;">Birth weight &lt;1 kg: IV, Oral: 3 to 6 mg/kg/dose twice <b>weekly</b> for up to 6 weeks or until IV access is no longer required; usually initiated within 48 to 72 hours of birth (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-AAP.2'])">Ref</a></span>). NICU-specific <i>Candida</i> sp. susceptibility patterns/minimum inhibitory concentration (MIC) distributions may be considered when selecting the dose; 3 mg/kg/dose is likely to be effective when local <i>Candida </i>isolate MICs are ≤2 mg/L; 6 mg/kg/dose is necessary when MICs are &gt;2 mg/L or are unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27401564','lexi-content-ref-19593252']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27401564','lexi-content-ref-19593252'])">Ref</a></span>); when MICs are low within a NICU, 3 mg/kg is likely as efficacious as 6 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33603574','lexi-content-ref-28285752']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33603574','lexi-content-ref-28285752'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Late prophylaxis: </i>
<b>Note:</b> May be considered in patients ≥8 days PNA who are at high risk of invasive candidiasis and receiving broad-spectrum antibiotics, particularly in the setting of gastrointestinal disease; dosing is based on pharmacokinetic modeling and has not been evaluated prospectively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19593252']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19593252'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm and term neonates: IV, Oral:</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Gestational Age</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Postnatal Age</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Dose</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">23 to &lt;30 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">8 to &lt;42 days</p></td>
<td align="left">
<p style="text-indent:0em;">6 mg/kg/dose every 72 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">≥42 days</p></td>
<td align="left">
<p style="text-indent:0em;">6 mg/kg/dose every 48 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">30 to 40 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">8 to &lt;42 days</p></td>
<td align="left">
<p style="text-indent:0em;">6 mg/kg/dose every 48 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, systemic (including Candidemia and invasive candidiasis); treatment: Note:</b> Alternative treatment for patients who have <b>not </b>received fluconazole prophylaxis.</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates: IV, Oral: 12 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>). Based on pharmacokinetic studies, a loading dose of 25 mg/kg, followed by 12 mg/kg/dose once daily achieves the desired AUC within 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2','lexi-content-ref-29744900','lexi-content-ref-26679628','lexi-content-ref-21085048','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2','lexi-content-ref-29744900','lexi-content-ref-26679628','lexi-content-ref-21085048','lexi-content-ref-AAP.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, CNS infection; step-down therapy: </b>Preterm and term neonates: IV, Oral: 12 mg/kg/dose once daily until all signs, symptoms, and CSF and radiological abnormalities have resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, esophageal and oropharyngeal (thrush); treatment: Note:</b> For oropharyngeal candidiasis, treat for 7 to 14 days. For esophageal candidiasis, treat for 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2','lexi-content-ref-manu.1'])">Ref</a></span>): IV, Oral:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">Gestational Age</p></th>
<th align="left">
<p style="text-indent:0em;">Postnatal Age</p></th>
<th align="left">
<p style="text-indent:0em;">Dose on Day 1<sup>a</sup></p></th>
<th align="left">
<p style="text-indent:0em;">Dose on Subsequent Days<sup>a</sup></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>a</sup> Doses up to 12 mg/kg/day have been used based on clinical judgement.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>b</sup> Change frequency to every 24 hours after the first 2 weeks of life.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">26 to 29 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">≤14 days</p></td>
<td align="left">
<p style="text-indent:0em;">6 mg/kg</p></td>
<td align="left">
<p style="text-indent:0em;">3 to 6 mg/kg/dose every 72 hours<sup>b</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;14 days</p></td>
<td align="left">
<p style="text-indent:0em;">6 mg/kg</p></td>
<td align="left">
<p style="text-indent:0em;">3 to 6 mg/kg/dose once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;29 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">All</p></td>
<td align="left">
<p style="text-indent:0em;">6 mg/kg</p></td>
<td align="left">
<p style="text-indent:0em;">3 to 6 mg/kg/dose once daily</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, extracorporeal membrane oxygenation (ECMO) patients: </b>Limited data available; dosing based on a pharmacokinetic study of pediatric patients (including neonates):</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonates:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Prophylaxis:</i> IV: 12 mg/kg on day 1, followed by 6 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2','lexi-content-ref-25896706']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2','lexi-content-ref-25896706'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment:</i> IV: 35 mg/kg on day 1, followed by 12 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2','lexi-content-ref-25896706','lexi-content-ref-30033691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2','lexi-content-ref-25896706','lexi-content-ref-30033691'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Coccidioidomycosis:</b> Limited data available; optimal dose has not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates: IV, Oral: 6 to 12 mg/kg/dose once daily. Treatment duration for confirmed infection depends on site and severity of infection and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27470238','lexi-content-ref-34310505','lexi-content-ref-35895879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27470238','lexi-content-ref-34310505','lexi-content-ref-35895879'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment in kidney impairment:</b> There are no specific neonatal dosage adjustments provided in the manufacturer's labeling; some experts have suggested the following indication-specific dosing based on pharmacokinetic studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19593252']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19593252'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Candidiasis, prophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Early prophylaxis: </i>
<b>Note: </b>Dosing based on usual dose of 6 mg/kg/dose twice weekly.</p>
<p style="text-indent:-2em;margin-left:8em;">Preterm neonates: GA 23 to 29 weeks, PNA ≥3 days, and S<sub>Cr</sub> 1.3 to 2 mg/dL: IV, Oral: 6 mg/kg/dose once weekly; resume 6 mg/kg/dose <b>twice</b> weekly when S<sub>Cr</sub> is ≤1 mg/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19593252']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19593252'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Late prophylaxis:</i>
<b> Note: </b>Dosing based on usual dose of 6 mg/kg/dose every 48 to 72 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Preterm and term neonates: PNA ≥8 days with S<sub>Cr</sub> ≥1.3 mg/dL: 6 mg/kg/dose once weekly; resume standard late prophylaxis dose for GA and PNA when S<sub>Cr</sub> is ≤1 mg/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19593252']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19593252'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F171707"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing, susceptible infection:</b> Infants, Children, and Adolescents: IV, Oral: Initial: 6 to 12 mg/kg/dose on day 1, followed by 3 to 12 mg/kg/dose once daily; duration and dosage depends on severity of infection; the manufacturer suggests limiting dose to 600 mg/dose; however, higher maximum doses have been used; see specific indications.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3d5255b1-0d87-4f3c-9f18-a8b5331d393b">Candida infections, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candida infections, prophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oncology patients at high risk of invasive candidiasis (eg, AML, recurrent ALL, myelodysplastic syndrome [MDS], HSCT recipients)</i>: Limited data available: Infants, Children, and Adolescents: IV, Oral: 6 to 12 mg/kg/dose once daily; maximum dose: 400 mg/dose; duration dependent upon type of transplant and/or chemotherapy, consult institution-specific protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23137136','lexi-content-ref-24424789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23137136','lexi-content-ref-24424789'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Surgical prophylaxis</i>
<i>, </i>
<i>high-risk patients undergoing liver, pancreas, kidney, or pancreas-kidney transplantation</i>: Infants, Children, and Adolescents: IV: 6 mg/kg as a single dose 60 minutes before procedure; maximum dose: 400 mg/dose; time of initiation and duration varies with transplant type, consult institution-specific protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a7a487bb-a32b-410e-85bb-cea78c6c85cb">Candidiasis, systemic, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, systemic (including Candidemia and invasive candidiasis), treatment:</b> Infants, Children, and Adolescents: IV, Oral: 12 mg/kg/dose once daily; maximum dose: 800 mg/dose; continue treatment for ≥14 days after documented clearance, resolution of symptoms, and resolution of neutropenia if present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23137136','lexi-content-ref-HHS.1','lexi-content-ref-26679628','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23137136','lexi-content-ref-HHS.1','lexi-content-ref-26679628','lexi-content-ref-AAP.1'])">Ref</a></span>). An initial loading dose of 25 mg/kg has also been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="006db5d6-8269-4d85-8ef5-4742cbdd03d0">Candidiasis, CNS candidiasis, step-down therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, CNS candidiasis, step-down therapy</b>
<i>:</i> Infants, Children, and Adolescents: Oral, IV: 12 mg/kg/dose once daily following initial therapy with liposomal amphotericin B (with or without flucytosine); maximum dose: 800 mg/dose; treatment should continue until all signs, symptoms, and CSF and radiological abnormalities have resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-28203777','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-28203777','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e695300a-55f5-4d15-9105-a52ec11fa4cc">Candidiasis, endophthalmitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, endophthalmitis, treatment:</b> Infants, Children, and Adolescents: Oral, IV: 12 mg/kg/dose once daily for at least 4 to 6 weeks until examination indicates resolution; maximum dose: 800 mg/dose. <b>Note: </b>Use in combination with intravitreal injection of voriconazole or amphotericin B deoxycholate when vitritis or macular involvement is present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>). An initial loading dose of 25 mg/kg has also been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2bd63e09-635f-4b3b-ac73-b3f4a49de4b5">Candidiasis, esophageal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, esophageal:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Oral, IV: 6 to 12 mg/kg/dose once daily for 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.1','lexi-content-ref-26679628','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.1','lexi-content-ref-26679628','lexi-content-ref-AAP.1'])">Ref</a></span>); maximum dose: 600 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>). <b>Note:</b> An initial loading dose of 25 mg/kg has also been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral, IV: 6 to 12 mg/kg/dose once daily for 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-26679628','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-26679628','lexi-content-ref-AAP.1'])">Ref</a></span>); usual adult dose: 400 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>). <b>Note:</b> An initial loading dose of 25 mg/kg has also been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Suppressive therapy (secondary prophylaxis): </i>Patients with HIV: <b>Note: </b>Not typically recommended, but can be considered if experiencing frequent severe recurrent infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5','lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5','lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Oral: 6 to 12 mg/kg/dose three times weekly; maximum dose: 600 mg/dose. If daily administration is required, maximum dose is 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: 100 to 200 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d2df81f9-66f6-4326-8441-1b02ca222e78">Candidiasis, oropharyngeal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, oropharyngeal:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Oral: 6 to 12 mg/kg/dose once daily for 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.1'])">Ref</a></span>); maximum dose: 400 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: 6 mg/kg/dose once daily for 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1'])">Ref</a></span>); usual adult dose: 100 to 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5','lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Suppressive therapy (secondary prophylaxis): </i>Patients with HIV: <b>Note: </b>Not typically recommended, but can be considered if experiencing frequent severe recurrent infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5','lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5','lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Oral: 6 to 12 mg/kg/dose three times weekly; maximum dose: 600 mg/dose. If daily administration is required, maximum dose is 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: 100 to 200 mg once daily or three times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5','lexi-content-ref-26679628'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e3bcbda7-40d6-44b6-b43e-00be9fa9aa4c">Candidiasis, peritoneal dialysis-related infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, peritoneal dialysis-related infections</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Peritonitis: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment:</i> Intraperitoneal, IV, Oral: 6 to 12 mg/kg/dose every 24 to 48 hours; maximum dose: 400 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Prophylaxis for high-risk situations (eg, during antibiotic therapy or PEG placement): </i>IV, Oral: 3 to 6 mg/kg/dose every 24 to 48 hours; maximum dose: 200 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Exit-site or tunnel infection, treatment: Infants, Children, and Adolescents: Oral: 6 mg/kg/dose every 24 to 48 hours; maximum dose: 400 mg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0438c731-a168-44a4-b672-4e1b74af8c34">Candidiasis, vulvovaginal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, vulvovaginal:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Uncomplicated infections, treatment (independent of HIV status</i>): Adolescents: Oral: 150 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815','lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815','lexi-content-ref-HHS.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe infections, treatment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Non-HIV-exposed/-infected: Adolescents: Oral: 150 mg every 72 hours for 2 to 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815','lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">HIV-exposed/-infected: Adolescents: Oral: 100 to 200 mg once daily for ≥7 days; may follow with chronic suppressive therapy of 150 mg once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Recurrent infection, treatment</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Non HIV-exposed/-infected: Adolescents: Oral: Initial: 100 to 200 mg every 72 hours for 3 doses; followed by maintenance of 100 to 200 mg once weekly for 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815','lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">HIV-exposed/-infected: Adolescents: Oral: 100 to 200 mg once daily for ≥ 7 days; may follow with chronic suppressive therapy of 150 mg once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e7618769-1abb-4870-a82f-2884524eba73">Coccidioidomycosis, HIV-exposed/-infected</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Coccidioidomycosis, HIV-exposed/-infected</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.7','lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.7','lexi-content-ref-HHS.2'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild to moderate non-meningeal infection (eg, focal pneumonia): </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: IV, Oral: 6 to 12 mg/kg/dose once daily; maximum dose: 400 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: 400 mg once daily for ≥6 months.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe illness (diffuse pulmonary or disseminated non-meningitic disease) initial therapy if unable to use amphotericin or as step-down therapy:</i> Infants and Children: IV, Oral: 12 mg/kg/dose once daily; maximum dose: 800 mg/dose for a total of 1 year of treatment followed by secondary prophylaxis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Meningeal infection:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: IV, Oral: 12 mg/kg/dose once daily; maximum dose: 800 mg/dose, followed by lifelong secondary prophylaxis.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: IV, Oral: 400 to 800 mg once daily, followed by lifelong suppressive therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Secondary prophylaxis/chronic suppressive therapy:</i> Infants, Children, and Adolescents: Oral: 6 mg/kg/dose once daily; maximum dose: 400 mg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f939c77c-a730-44f8-9e97-60991ba6452d">Cryptococcal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cryptococcal infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate localized infection including pneumonia (not CNS), treatment:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Non HIV-exposed/-infected: </i>Infants, Children, and Adolescents: Oral: 6 to 12 mg/kg/dose once daily for 6 to 12 months. Usual adult dose is 400 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20047480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20047480'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>HIV-exposed/-infected: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children: IV, Oral: 12 mg/kg on day 1, then 6 to 12 mg/kg/dose once daily; maximum dose: 600 mg/dose; duration depends on severity and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: Oral: 400 mg daily for 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.7']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.7'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CNS, severe pulmonary or disseminate infection, treatment:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Induction therapy: HIV-exposed/-infected (not first-line therapy):</i></p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children: IV: 12 mg/kg on day 1, then 10 to 12 mg/kg/dose once daily in combination with amphotericin B or flucytosine for ≥14 days; maximum dose: 800 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: IV, Oral: 400 to 800 mg once daily in combination with flucytosine for ≥14 days <b>or </b>800 mg once daily in combination with amphotericin for ≥14 days<b> or</b> 1,200 mg once daily as monotherapy for at least 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.7']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.7'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Consolidation:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Non-HIV-exposed/-infected: </i>Infants, Children, and Adolescents: IV, Oral: 10 to 12 mg/kg/<b>day</b> once daily or in divided doses twice daily for 8 weeks; maximum dose: 800 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20047480','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20047480','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>HIV-exposed/-infected:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Infants and Children: IV, Oral: 12 mg/kg on day 1, then 10 to 12 mg/kg/day once daily for ≥8 weeks; maximum daily dose: 800 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Adolescents: IV, Oral: 400 mg once daily for ≥8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.7']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.7'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Secondary prophylaxis/chronic suppressive maintenance therapy: </i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Non-HIV-exposed/-infected: </i>Infants, Children, and Adolescents: Oral: 6 mg/kg/dose once daily for 6 to 12 months; maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20047480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20047480'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>HIV-exposed/-infected: </i>Infants, Children, and Adolescents: Oral: 6 mg/kg/dose once daily for ≥12 months; maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.7','lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.7','lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="da0b3cae-9a59-4ae8-9ed2-c6aad13abf2e">Histoplasmosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Histoplasmosis:</b> HIV-exposed/-infected patients, alternative therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.7','lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.7','lexi-content-ref-HHS.2'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary, acute primary disease:</i> Infants and Children: Oral: 3 to 6 mg/kg/dose once daily; maximum dose: 200 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Disseminated disease, mild to moderate:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: IV, Oral: 5 to 6 mg/kg/dose twice daily for 12 months; maximum dose: 300 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: 800 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Secondary prophylaxis/chronic</i>
<i> suppressive therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Oral: 3 to 6 mg/kg/dose once daily for ≥12 months; maximum dose: 200 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: 400 mg once daily for ≥12 months.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51110615"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing is based on pharmacokinetic parameters, limited pediatric studies, adult studies, and expert opinion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-7579091','lexi-content-ref-2184510','lexi-content-ref-14551347','lexi-content-ref-Rikken.1','lexi-content-ref-14969569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-7579091','lexi-content-ref-2184510','lexi-content-ref-14551347','lexi-content-ref-Rikken.1','lexi-content-ref-14969569'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7579091','lexi-content-ref-2184510','lexi-content-ref-14551347','lexi-content-ref-Rikken.1','lexi-content-ref-14969569','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7579091','lexi-content-ref-2184510','lexi-content-ref-14551347','lexi-content-ref-Rikken.1','lexi-content-ref-14969569','lexi-content-ref-manu.1'])">Ref</a></span>): <b>Note: </b>In critically ill patients with altered kidney function, consider monitoring serum concentrations if available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25148892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25148892'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥50 mL/minute/1.73 m<sup>2</sup>: IV, Oral: Administer the usual indication-specific dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;50 mL/minute/1.73 m<sup>2</sup>: IV, Oral: Administer the usual indication-specific dose every 48 hours <b>or</b> administer 100% of the usual indication-specific dose or loading dose initially, followed by 50% of the usual indication-specific dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> No dosage adjustment necessary for single-dose therapy for vaginal candidiasis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Based on adult information, fluconazole is dialyzable (33% to 38% with low-flux dialyzers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1623910','lexi-content-ref-2306414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1623910','lexi-content-ref-2306414'])">Ref</a></span>) or approximately 50% after a 3-hour session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV, Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Dialysis days: Administer the usual indication-specific dose after each dialysis session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2184510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2184510'])">Ref</a></span>). <b>Note:</b> The manufacturer's labeling recommends that in addition to 100% of the dose given after dialysis on dialysis days, patients should also receive a reduced dose according to their creatinine clearance on nondialysis days; however, based on adult data, this appears unnecessary, as fluconazole concentrations decrease only minimally during the interdialytic period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7579091','lexi-content-ref-14551347','lexi-content-ref-1623910','lexi-content-ref-2306414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7579091','lexi-content-ref-14551347','lexi-content-ref-1623910','lexi-content-ref-2306414'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV, Oral: Administer 50% of the usual indication-specific dose every 24 to 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-9385491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-9385491'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Flow rates vary widely in pediatric patients. Appropriate dosing requires consideration of drug penetration to site of infection, severity of illness, and consideration of loading dose. Close monitoring of response and adverse reactions due to drug accumulation is important. Due to limited data and patient variability, monitor serum concentrations if available (target AUC<sub>24</sub>/MIC 50 to 100 or trough concentrations 10 to 15 mg/L [for MICs up to 4 mg/L] in critical illness) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24379304','lexi-content-ref-32535150','lexi-content-ref-34683388','lexi-content-ref-25148892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24379304','lexi-content-ref-32535150','lexi-content-ref-34683388','lexi-content-ref-25148892'])">Ref</a></span>)­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­.</p>
<p style="text-indent:-2em;margin-left:4em;">CVVH/CVVHD/CVVHDF: Children and Adolescents: IV, Oral: Loading dose: 6 to 12 mg/kg once, followed by 6 to 12 mg/kg/dose (as appropriate for patient-specific indication) every 24 hours; maximum dose: 800 mg/dose. For some indications, a higher initial loading dose may be appropriate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.1','lexi-content-ref-14969569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-HHS.1','lexi-content-ref-14969569'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Fluconazole undergoes substantial tubular reabsorption in patients with normal kidney function. Because this reabsorption is absent in anuric patients receiving renal replacement therapy, total fluconazole clearance in adults receiving CRRT with rates of 1,500 to 3,000 mL/hour is 1.5 to 2.3 times that reported in healthy volunteers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16311263','lexi-content-ref-11206042','lexi-content-ref-11214774','lexi-content-ref-21930888','lexi-content-ref-9421318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16311263','lexi-content-ref-11206042','lexi-content-ref-11214774','lexi-content-ref-21930888','lexi-content-ref-9421318'])">Ref</a></span>). In one case report in an adolescent receiving CVVH with a high flow rate (4,090 mL/hour), the patient required double the initial dosage (to 20 mg/kg/<b>day</b>) to achieve pharmacodynamic targets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31259879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31259879'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51110616"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; use with caution.</p></div>
<div class="block doa drugH1Div" id="F171682"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8450" href="/d/html/8450.html" rel="external">see "Fluconazole: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6323927f-8b2e-4468-8728-4b7efd61e9f7">Blastomycosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Blastomycosis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CNS disease (alternative agent):</i> Step-down therapy: <b>Oral:</b> 800 mg once daily for ≥12 months and until resolution of cerebrospinal (CSF) abnormalities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18462107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18462107'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary disease (alternative agent):</i>
<b>Note:</b> Reserve for patients unable to tolerate itraconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18462107','lexi-content-ref-9332510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18462107','lexi-content-ref-9332510'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 400 to 800 mg once daily for 6 to 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18462107','lexi-content-ref-9332510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18462107','lexi-content-ref-9332510'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="04119584-1974-4656-a3ca-18c3e3348943">Candidiasis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider weight-based dosing for patients &lt;50 kg or &gt;90 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7935701','lexi-content-ref-12746765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7935701','lexi-content-ref-12746765'])">Ref</a></span>). A maximum dose has not been established, but based on a small number of patients, doses up to 1.6 g/day appear to be well tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7622915','lexi-content-ref-30535104','lexi-content-ref-9476509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7622915','lexi-content-ref-30535104','lexi-content-ref-9476509'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Candidemia:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Initial therapy (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> For use in patients without neutropenia who are not critically ill and not at high risk of fluconazole-resistant isolate. For use in patients with neutropenia who are not critically ill and have had no prior azole exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>); some experts reserve for patients with neutropenia who cannot be treated with other agents and whose ANC is &gt;500 and increasing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vazquez.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vazquez.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV, Oral:</b> Loading dose of 800 mg (or 12 mg/kg) on day 1, then 400 mg (or 6 mg/kg) once daily; if fluconazole-susceptible <i>Candida glabrata </i>isolated, transition to 800 mg (or 12 mg/kg) once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Step-down therapy:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Isolates other than <i>C. glabrata</i>: <b>Oral:</b> 400 mg (or 6 mg/kg) once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Isolates of <i>C. glabrata </i>(if fluconazole-susceptible or susceptible dose-dependent): <b>Oral:</b> 800 mg (or 12 mg/kg) once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-Vazquez.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-Vazquez.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Duration:</b> Continue for ≥14 days after first negative blood culture and resolution of signs/symptoms (longer duration required in patients with metastatic complications); step-down therapy to oral fluconazole (eg, after initial therapy with an echinocandin) is recommended after 5 to 7 days in stable patients with negative repeat cultures and fluconazole-susceptible isolates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-Vazquez.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-Vazquez.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cardiac infection, native or prosthetic valve endocarditis, or device infection (eg, implantable cardiac defibrillator, pacemaker, ventricular assist device [VAD]):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Step-down therapy (for patients who are clinically stable and have responded to initial therapy with negative repeat cultures):<b> IV, Oral:</b> 400 to 800 mg (or 6 to 12 mg/kg) once daily (IDSA [Pappas 2016]).</p>
<p style="text-indent:-2em;margin-left:6em;">Duration: For device infection without endocarditis, ≥4 weeks after device removal (4 weeks for generator pocket infections and ≥6 weeks after device removal for wire infections). If VAD cannot be removed, continue chronic suppressive therapy for as long as the VAD remains in place with fluconazole 400 to 800 mg (or 6 to 12 mg/kg) once daily. For endocarditis, ≥6 weeks after valve replacement surgery, with longer duration for perivalvular abscesses or other complications; long-term suppressive therapy is recommended for prosthetic valve endocarditis or if valve cannot be replaced (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CNS:</i> Step-down therapy: <b>IV, Oral:</b> 400 to 800 mg (or 6 to 12 mg/kg) once daily; continue until signs/symptoms and CSF/radiologic abnormalities have resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-28203777'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Endophthalmitis, endogenous (with or without vitritis):</i>
<b>IV, Oral:</b> Loading dose of 800 mg (or 12 mg/kg) on day 1, then 400 to 800 mg (or 6 to 12 mg/kg) once daily for ≥4 to 6 weeks and until examination indicates resolution (longer duration may be needed for patients with vitritis); for patients with vitritis or macular involvement, intravitreal antifungal therapy is also recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Esophageal, treatment:</i>
<b> IV, Oral:</b> 400 mg (or 6 mg/kg) on day 1, then 200 to 400 mg (or 3 to 6 mg/kg) once daily for 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31155770','lexi-content-ref-16231260','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31155770','lexi-content-ref-16231260','lexi-content-ref-26679628'])">Ref</a></span>). Some experts increase to 800 mg once daily for those with <i>C. albicans</i> infection who do not respond after 1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kauffman.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kauffman.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Esophageal, chronic suppression for recurrent infection:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Suppressive therapy is usually unnecessary. Reserve for patients who are immunocompromised (eg, with HIV and low CD4 count) who have multiple recurrent infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16231260','lexi-content-ref-Kauffman.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16231260','lexi-content-ref-Kauffman.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 100 to 200 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kauffman.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kauffman.3'])">Ref</a></span>). Some experts suggest 100 to 200 mg 3 times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16231260','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16231260','lexi-content-ref-26679628'])">Ref</a></span>); however, resistance may be a potential concern (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kauffman.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kauffman.3'])">Ref</a></span>). May discontinue once immune reconstitution occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16231260','lexi-content-ref-Kauffman.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16231260','lexi-content-ref-Kauffman.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatosplenic, chronic disseminated:</i> Step-down therapy:<b> Oral:</b> 400 mg (or 6 mg/kg) once daily; continue until lesion resolution (usually several months) and through periods of immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intertrigo, refractory to topical therapy (off-label use):</i>
<b>Oral:</b> 150 mg once weekly for 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brodell.2018','lexi-content-ref-9762826','lexi-content-ref-8002145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brodell.2018','lexi-content-ref-9762826','lexi-content-ref-8002145'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intra-abdominal infection, acute, including peritonitis and/or abscess (alternative agent):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>For empiric therapy, reserve as an alternative to an echinocandin if no previous azole exposure, noncritically ill, and not at high risk of fluconazole-resistant isolate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-Kauffman.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-Kauffman.4'])">Ref</a></span>). Step-down therapy (after patient has responded to initial therapy [eg, echinocandin]) with fluconazole is recommended in stable patients with confirmed susceptibility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-Kauffman.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-Kauffman.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, Oral:</b> 800 mg (or 12 mg/kg) on day 1, then 400 mg (or 6 mg/kg) once daily. Total antifungal duration is ≥14 days based on source control and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31155770','lexi-content-ref-26679628','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31155770','lexi-content-ref-26679628','lexi-content-ref-28085573'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oropharyngeal: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Reserve for moderate to severe disease, poor response to topical treatment, or recurrent infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-Kauffman.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-Kauffman.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, Oral:</b> 200 mg on day 1, then 100 to 200 mg once daily for 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31155770','lexi-content-ref-HHS.8','lexi-content-ref-Kauffman.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31155770','lexi-content-ref-HHS.8','lexi-content-ref-Kauffman.5'])">Ref</a></span>); some experts increase to 400 mg once daily for those who do not initially respond (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kauffman.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kauffman.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oropharyngeal, chronic suppression for recurrent infection: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Suppressive therapy is usually unnecessary. Reserve for patients who are immunocompromised (eg, with HIV and low CD4 count) who have multiple recurrent infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kauffman.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kauffman.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kauffman.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kauffman.5'])">Ref</a></span>). Some experts suggest 100 mg 3 times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>); however, resistance may be a potential concern (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kauffman.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kauffman.5'])">Ref</a></span>). May discontinue once immune reconstitution occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-Kauffman.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-Kauffman.5'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Osteoarticular (osteomyelitis or septic arthritis):</i> Initial or step-down therapy: <b>IV, Oral:</b> 400 mg (or 6 mg/kg) once daily. Duration for osteomyelitis is 6 to 12 months and for septic arthritis is 6 weeks. Course may include 2 weeks of initial treatment with a lipid formulation of amphotericin B or an echinocandin. For prosthetic joints that cannot be removed, chronic suppressive therapy with fluconazole 400 mg (or 6 mg/kg) once daily is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Peritonitis, associated with peritoneal dialysis:</i>
<b>Note:</b> Use for empiric treatment if no prior azole exposure or for directed therapy with confirmed susceptibility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Glickman.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Glickman.2018'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, Oral:</b> 200 mg on day 1, then 100 to 200 mg once daily for 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15181494','lexi-content-ref-Glickman.2018','lexi-content-ref-27282851','lexi-content-ref-11096043']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15181494','lexi-content-ref-Glickman.2018','lexi-content-ref-27282851','lexi-content-ref-11096043'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Thrombophlebitis, suppurative:</i> Initial or step-down therapy: <b>IV, Oral:</b> 400 to 800 mg (or 6 to 12 mg/kg) once daily for ≥2 weeks after candidemia (if present) has cleared (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urinary tract infection:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Candiduria (asymptomatic):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients with neutropenia:</i> Treat as if patient has candidemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23170870','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23170870','lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients undergoing a urologic procedure:</i>
<b>Oral:</b> 400 mg (or 6 mg/kg) once daily several days before and after the procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cystitis (symptomatic): <b>Oral:</b> 200 mg (or 3 mg/kg) once daily for 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Pyelonephritis: <b>Oral:</b> 200 to 400 mg (or 3 to 6 mg/kg) once daily for 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Urinary tract infection associated with fungus balls: <b>Oral:</b> 200 to 400 mg (or 3 to 6 mg/kg) once daily; concomitant amphotericin B deoxycholate irrigation via nephrostomy tubes, if present, is also recommended, along with surgical management (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Vulvovaginal:</i>
<b>Note:</b> Not recommended for infection due to <i>C. glabrata</i> or <i>C. krusei</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Mild or moderate infection in immunocompetent patient: <b>Oral:</b> 150 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-26679628','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-26679628','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Severe infection or infection in immunocompromised patient: <b>Oral:</b> 150 mg every 72 hours for 2 or 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Recurrent infection:</p>
<p style="text-indent:-2em;margin-left:8em;">Fluconazole monotherapy: <b>Oral:</b> 150 mg every 72 hours for 10 to 14 days, followed by 150 mg once weekly for 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-15329425']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-15329425'])">Ref</a></span>) <b>or</b> 100 mg, 150 mg, or 200 mg every 72 hours for 3 doses, then 100 mg, 150 mg, or 200 mg once weekly for 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Combination therapy with oteseconazole: <b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:10em;">Days 1 to 7: <b>Fluconazole</b> 150 mg as a single dose on days 1, 4, and 7 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vivjoa.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vivjoa.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Days 14 to 20: <b>Oteseconazole</b> 150 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vivjoa.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vivjoa.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Starting on day 28: <b>Oteseconazole</b> 150 once weekly for 11 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vivjoa.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vivjoa.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="782291f3-a44f-4afe-aca5-08f6387c4d9d">Candidiasis, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, prophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">High-risk patients in the ICU in units with a high rate (&gt;5%) of invasive candidiasis (off-label use): <b>Oral, IV:</b> Loading dose of 800 mg (or 12 mg/kg) once on day 1, then 400 mg (or 6 mg/kg) once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Patients with hematologic malignancy (off-label use) or hematopoietic cell transplant (HCT) recipients who do <b>not</b> warrant mold-active prophylaxis (off-label use): <b>Oral:</b> 400 mg once daily. Duration is at least until resolution of neutropenia and/or through day 75 in allogeneic HCT recipients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629','lexi-content-ref-30179565','lexi-content-ref-16339606','lexi-content-ref-Wingard.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629','lexi-content-ref-30179565','lexi-content-ref-16339606','lexi-content-ref-Wingard.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis-associated infection (concurrently treated with antibacterials), prevention of secondary fungal infection: <b>Oral:</b> 200 mg every other day or 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Glickman.2018','lexi-content-ref-20634438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Glickman.2018','lexi-content-ref-20634438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Solid organ transplant recipients (selected patients at high-risk for <i>Candida</i> infection) (off-label use): <b>Oral, IV:</b> 400 mg (or 6 mg/kg) given perioperatively and continued once daily postoperatively; indications and duration vary among transplant centers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981','lexi-content-ref-Fishman.2018','lexi-content-ref-12352887']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981','lexi-content-ref-Fishman.2018','lexi-content-ref-12352887'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5152cf1-71f9-4f9f-a799-ede3830e0bc9">Coccidioidomycosis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Coccidioidomycosis, treatment (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Initial parenteral antifungal therapy with amphotericin B is warranted for severe disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.8','lexi-content-ref-27470238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.8','lexi-content-ref-27470238'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Bone and/or joint infection:</i> Initial or step-down therapy: <b>Oral:</b> 800 mg once daily for ≥3 years; in some cases, lifelong treatment is needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.8','lexi-content-ref-27470238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.8','lexi-content-ref-27470238'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Meningitis:</i>
<b> Oral:</b> 400 mg to 1.2 g once daily, depending on severity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27470238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27470238'])">Ref</a></span>); some experts favor a starting dose of ≥800 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30924967','lexi-content-ref-Blair.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30924967','lexi-content-ref-Blair.1'])">Ref</a></span>). Duration is lifelong because of the high relapse rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.8','lexi-content-ref-27470238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.8','lexi-content-ref-27470238'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pneumonia, primary infection:</i>
<b>Note:</b> Reserve for patients with or at risk for severe disease (eg, extensive pulmonary involvement, patients who are immunocompromised) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.8','lexi-content-ref-27470238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.8','lexi-content-ref-27470238'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Usual dose: 400 mg once daily; IDSA guidelines state that some experts recommend 800 mg once daily. For severe disease, use in combination with initial therapy with amphotericin B. Duration is typically 3 to 6 months, but can vary depending on comorbid conditions, severity of disease, and response to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.8','lexi-content-ref-27470238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.8','lexi-content-ref-27470238'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pneumonia, symptomatic chronic cavitary and/or cavitary disease in patients who are immunocompromised:</i>
<b>Oral:</b> 400 mg once daily for ≥12 months. In patients with ruptured cavities, the duration may be shorter, but depends upon the postoperative course (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27470238','lexi-content-ref-Jaroszewski.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27470238','lexi-content-ref-Jaroszewski.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Soft tissue infection (not associated with bone infection):</i>
<b>Oral:</b> 400 mg once daily; some experts give up to 800 mg once daily; duration is for ≥6 to 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27470238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27470238'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="739d890e-0e4d-43a1-97a3-3b7dc8ba75cf">Coccidioidomycosis, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Coccidioidomycosis, prophylaxis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients with HIV:</i>
<b>Note:</b> Primary prophylaxis is not recommended; yearly or twice-yearly serologic testing should be performed in patients living in endemic areas.</p>
<p style="text-indent:-2em;margin-left:6em;">Patients with a CD4 count &lt;250 cells/mm<sup>3</sup> who have a new positive serology: <b>Oral:</b> 400 mg once daily until antiretroviral therapy has fully suppressed HIV replication and the CD4 count is ≥250 cells/mm<sup>3</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.8']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.8'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Solid organ transplant recipients: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Seronegative patients in endemic areas (regardless of clinical history of coccidioidomycosis): <b>Oral:</b> 200 mg once daily for 6 to 12 months following transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30924967','lexi-content-ref-27470238','lexi-content-ref-37080658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30924967','lexi-content-ref-27470238','lexi-content-ref-37080658'])">Ref</a></span>); some experts favor 400 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ampel.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ampel.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Seropositive patients in endemic areas: <b>Oral:</b> 400 mg once daily for 6 to 12 months following transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30924967','lexi-content-ref-27470238','lexi-content-ref-37080658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30924967','lexi-content-ref-27470238','lexi-content-ref-37080658'])">Ref</a></span>); some experts favor 400 mg once daily for 12 months posttransplantation followed by 200 mg once daily for the duration of immunosuppressive therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ampel.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ampel.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4e92319c-5908-4496-91af-dd3d80f81fad">Cryptococcal meningitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cryptococcal meningitis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients with HIV:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Induction:<b> Note:</b> Induction therapy should be continued beyond the durations listed below if clinical improvement is not observed and/or if CSF cultures remain positive (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cox.2018a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cox.2018a'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Resource-rich settings, alternative regimens:</i></p>
<p style="text-indent:-2em;margin-left:10em;">If flucytosine is unavailable or not tolerated: <b>Oral: </b>800 mg to 1.2 g once daily in combination with amphotericin B (lipid formulation preferred) for ≥2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.8']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.8'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">If amphotericin B is unavailable or not tolerated: <b>Oral: </b>1.2 g once daily in combination with flucytosine for ≥2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.8','lexi-content-ref-20047480','lexi-content-ref-29539274','lexi-content-ref-20038244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.8','lexi-content-ref-20047480','lexi-content-ref-29539274','lexi-content-ref-20038244'])">Ref</a></span>). <b>Note:</b> Some experts use 800 mg once daily in combination with flucytosine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.8']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.8'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">If flucytosine and amphotericin B are unavailable or not tolerated: <b>Oral: </b>1.2 g once daily as monotherapy for ≥2 weeks. <b>Note:</b> Efficacy is decreased with fluconazole monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.8']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.8'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Resource-limited settings:</i></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 1.2 g once daily for 2 weeks in combination with flucytosine and a single dose of liposomal amphotericin B (preferred regimen) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35320642','lexi-content-ref-WHO.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35320642','lexi-content-ref-WHO.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">If liposomal amphotericin B is not available: <b>Oral:</b> 1.2 g once daily for 1 week, started <b>after</b> completion of 1 week of amphotericin B deoxycholate in combination with flucytosine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">If no amphotericin B formulation is available: <b>Oral:</b> 1.2 g once daily in combination with flucytosine for 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">If flucytosine is unavailable: <b>Oral:</b> 1.2 g once daily in combination with liposomal amphotericin B or amphotericin B deoxycholate for 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Consolidation: <b>Oral:</b> 800 mg once daily for ≥8 weeks; may consider reducing dose to 400 mg once daily in patients who are treated with amphotericin B and flucytosine induction regimen, have negative CSF cultures after 2 weeks of induction therapy, and are initiated on antiretroviral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.8','lexi-content-ref-20047480','lexi-content-ref-WHO.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.8','lexi-content-ref-20047480','lexi-content-ref-WHO.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance (suppression): <b>Oral:</b> 200 mg once daily for ≥12 months; may discontinue if completed induction, consolidation, and ≥12 months of maintenance therapy, patient remains asymptomatic, and CD4 count has been ≥100 cells/mm<sup>3</sup> for ≥3 months and HIV RNA is suppressed in response to effective antiretroviral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.8']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.8'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients without HIV:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Induction (alternative regimens):</p>
<p style="text-indent:-2em;margin-left:8em;">If flucytosine is unavailable or not tolerated: <b>Oral: </b>800 mg once daily in combination with amphotericin B for 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cox.2018b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cox.2018b'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">If amphotericin B is unavailable or not tolerated: <b>Oral: </b>800 mg to 1.2 g once daily in combination with flucytosine for 2 to 10 weeks, depending on severity and response to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cox.2018b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cox.2018b'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">If amphotericin B and flucytosine are unavailable or not tolerated: <b>Oral: </b>1.2 g once daily as monotherapy for ≥10 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cox.2018b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cox.2018b'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Consolidation: <b>Oral:</b> 400 to 800 mg once daily for 8 weeks (some experts prefer 800 mg once daily for patients who receive a 2-week induction course) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-Cox.2018b','lexi-content-ref-20047480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-Cox.2018b','lexi-content-ref-20047480'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance (suppression): <b>Oral:</b> 200 to 400 mg once daily for 6 to 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-20047480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-20047480'])">Ref</a></span>). A longer duration may be warranted for patients receiving very high doses of immunosuppression (eg, high-dose steroids or biologic agents [eg, alemtuzumab]) or with radiographic evidence of cryptococcoma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-Cox.2018b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-Cox.2018b'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="00553653-e085-4d92-aa4e-f44ea231aa47">Cryptococcosis, pulmonary infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cryptococcosis, pulmonary infection (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate symptoms (if severe pneumonia, treat like CNS infection): Immunocompetent or immunocompromised patients without diffuse pulmonary infiltrates or disseminated infection: <b>Oral:</b> 400 mg once daily for 6 to 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-Cox.2018c','lexi-content-ref-20047480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-Cox.2018c','lexi-content-ref-20047480'])">Ref</a></span>); for patients with HIV, some experts recommend 400 to 800 mg once daily for 10 weeks, followed by 200 mg once daily for a total of 6 months in combination with effective antiretroviral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.8']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.8'])">Ref</a></span>). Chronic suppressive therapy may be warranted for patients with ongoing immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-Cox.2018c']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-Cox.2018c'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64502832-afb2-4634-b4cc-9964152e6c0b">Onychomycosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Onychomycosis (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients unable to use preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25409999']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25409999'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 150 to 450 mg once weekly. Usual duration of therapy: 3 months (fingernail) or 6 to 12 months (toenail) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25409999','lexi-content-ref-9631990','lexi-content-ref-9631989']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25409999','lexi-content-ref-9631990','lexi-content-ref-9631989'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="15c0a5bc-b04b-4bce-808a-eba28afcd673">Tinea infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tinea infections (alternative agent) (off-label use): Note:</b> For disease that is extensive or refractory to topical therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldstein.2018','lexi-content-ref-Goldstein.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldstein.2018','lexi-content-ref-Goldstein.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tinea corporis/tinea cruris:</i>
<b>Oral:</b> 150 to 200 mg once weekly for 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldstein.2018','lexi-content-ref-24610666','lexi-content-ref-1562699','lexi-content-ref-9568414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldstein.2018','lexi-content-ref-24610666','lexi-content-ref-1562699','lexi-content-ref-9568414'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tinea pedis/tinea manuum:</i>
<b>Oral:</b> 150 mg once weekly for 2 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldstein.2018','lexi-content-ref-18478357','lexi-content-ref-24610666','lexi-content-ref-1562699']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldstein.2018','lexi-content-ref-18478357','lexi-content-ref-24610666','lexi-content-ref-1562699'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tinea versicolor (pityriasis versicolor):</i>
<b>Oral:</b> 300 mg once weekly for 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15841655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15841655'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990605"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Altered kidney function: Note:</b> Renal function estimated using the Cockcroft-Gault formula.</p>
<p style="text-indent:-2em;margin-left:4em;">No adjustment for vaginal candidiasis single-dose therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">For multiple dosing, administer 100% of the indication-specific loading/initial dose recommended in the adult dosing section, then adjust daily doses as follows: IV, Oral (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7579091','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7579091','lexi-content-ref-manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CrCl &gt;50 mL/minute:</i> No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CrCl ≤50 mL/minute:</i> Reduce dose by 50%.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b>
<b>IV, Oral:</b> Dialyzable (33% to 38% with low-flux dialyzers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1623910','lexi-content-ref-2306414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1623910','lexi-content-ref-2306414'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Three-times-weekly (postdialysis) dosing: </i>No dosage adjustment necessary for indication-specific loading/initial or maintenance dose recommended in the adult dosing section; however, only administer maintenance doses 3 times/week (on dialysis days) after the dialysis session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7579091','lexi-content-ref-14551347','lexi-content-ref-1623910','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7579091','lexi-content-ref-14551347','lexi-content-ref-1623910','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> The manufacturer's labeling recommends that in addition to 100% of the dose given after dialysis on dialysis days, patients should also receive a reduced dose according to their creatinine clearance on nondialysis days; however, this appears unnecessary, as fluconazole concentrations decrease only minimally during the interdialytic period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7579091','lexi-content-ref-14551347','lexi-content-ref-1623910','lexi-content-ref-2306414','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7579091','lexi-content-ref-14551347','lexi-content-ref-1623910','lexi-content-ref-2306414','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Once-daily dosing (may be considered when a more convenient dosing regimen is preferred [eg, hospitalized patients]):</i> Administer 100% of the indication-specific loading/initial dose recommended in the adult dosing section, then reduce maintenance dose by 50% and administer once daily; when scheduled dose falls on a dialysis day, administer after dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> Initial: Administer 100% of the indication-specific loading/initial dose recommended in the adult dosing section; reduce maintenance doses by 50% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14551347','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14551347','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour), unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">CVVH/CVVHD/CVVHDF: <b>IV, Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">If the usual recommended dose is 200 mg once daily, administer 400 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>) (see note regarding increased clearance in patients receiving renal replacement therapy below).</p>
<p style="text-indent:-2em;margin-left:6em;">If the usual recommended dose is 400 mg once daily, administer an 800 mg loading dose, followed by maintenance doses of 800 mg/day in 1 to 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16311263','lexi-content-ref-11206042','lexi-content-ref-11214774','lexi-content-ref-21930888']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16311263','lexi-content-ref-11206042','lexi-content-ref-11214774','lexi-content-ref-21930888'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">If the usual recommended dose is 800 mg once daily, administer a 1.2 g loading dose, followed by maintenance doses of 1.2 g/day in 1 to 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>) (see note regarding increased clearance in patients receiving renal replacement therapy below).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Fluconazole undergoes substantial tubular reabsorption in patients with normal kidney function. Because this reabsorption is absent in anuric patients receiving renal replacement therapy, total fluconazole clearance during CRRT with rates of 1,500 to 3,000 mL/hour is <b>1.5 to 2.3</b> times that reported in healthy volunteers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16311263','lexi-content-ref-11206042','lexi-content-ref-11214774','lexi-content-ref-21930888','lexi-content-ref-9421318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16311263','lexi-content-ref-11206042','lexi-content-ref-11214774','lexi-content-ref-21930888','lexi-content-ref-9421318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">PIRRT (effluent flow rate 4 to 5 L/hour, 8- to 10-hour session given every day):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, Oral:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Loading dose</i>:</p>
<p style="text-indent:-2em;margin-left:10em;">Administer 100% of the recommended indication-specific loading dose recommended in the adult dosing section.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Maintenance dose: </i>
<b>Note:</b> Optimal dose not well established. Select dose based on pathogen, minimum inhibitory concentration, immunocompromised state, and disease severity.</p>
<p style="text-indent:-2em;margin-left:10em;">400 mg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25455854','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25455854','lexi-content-ref-Expert.DOR'])">Ref</a></span>) or twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27251341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27251341'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987619"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The hepatic dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST, Jeong Park, PharmD, MS, BCTXP, FCCP, FAST, Arun Jesudian, MD, Sasan Sakiani, MD</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Child-Turcotte-Pugh class A to C: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34250196','lexi-content-ref-8448970','lexi-content-ref-7592177','lexi-content-ref-25806406']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34250196','lexi-content-ref-8448970','lexi-content-ref-7592177','lexi-content-ref-25806406'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment in patients with chronic, worsening hepatic function during treatment (eg, progression from Child-Turcotte-Pugh class A to B):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Progression from baseline to Child-Turcotte-Pugh class A to C: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8448970','lexi-content-ref-7592177']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8448970','lexi-content-ref-7592177'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute worsening of hepatic function (eg, requiring hospitalization): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Child-Turcotte-Pugh class A through C</b>: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31762485','lexi-content-ref-7592177']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31762485','lexi-content-ref-7592177'])">Ref</a></span>). If fluconazole-induced liver injury is suspected, usually resolves without intervention. If intervention is required, liver injury is generally reversible within ~2 weeks after dose reduction or discontinuation but may recur upon rechallenge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093949','lexi-content-ref-27927037','lexi-content-ref-20308378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093949','lexi-content-ref-27927037','lexi-content-ref-20308378'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F55687637"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dysrhythmias: Azole antifungals, including fluconazole, have been associated with <b>prolonged QT interval on ECG</b>, which may lead to <b>torsades de pointes </b>(TdP) or polymorphic ventricular arrhythmias. Numerous probable cases of TdP have been reported with fluconazole in patients with additional risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12495173','lexi-content-ref-18359968','lexi-content-ref-16849620','lexi-content-ref-20297862','lexi-content-ref-11302406']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12495173','lexi-content-ref-18359968','lexi-content-ref-16849620','lexi-content-ref-20297862','lexi-content-ref-11302406'])">Ref</a></span>). Drug-drug interactions commonly play a role in risk related to cardiac effects with fluconazole either by an additive pharmacodynamic effect, reducing the clearance of fluconazole, or by lowering potassium and/or magnesium concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14686224','lexi-content-ref-29644223','lexi-content-ref-23229485']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14686224','lexi-content-ref-29644223','lexi-content-ref-23229485'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Vascular: Another rare cardiac effect with fluconazole is hypersensitivity coronary syndrome (ie, allergic angina or Kounis syndrome) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26938747']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26938747'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Dysrhythmias: One proposed mechanism is that azole antifungals may block the I<sub>Kr</sub> channel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19499872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19499872'])">Ref</a></span>). Another possible mechanism is depression of rapidly activating delayed rectifier potassium channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11302406']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11302406'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Vascular: Kounis syndrome is thought to be caused by an allergen mediated-IgE and mast cell activation and degranulation causing histamine release (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26938747']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26938747'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Dysrhythmias: Rapid; QT prolongation occurred within the first 24 hours to a couple of days after initiation, dependent on drug-drug interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27212965']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27212965'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Vascular: Kounis syndrome may occur immediately after the first dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26938747']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26938747'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced QTc prolongation/TdP (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Structural heart disease (eg, history of myocardial infarction or heart failure with reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Longer baseline QTc interval (eg, &gt;450 msec) or lengthening of the QTc by ≥60 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12495173','lexi-content-ref-16849620','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12495173','lexi-content-ref-16849620','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Electrolyte disturbances (eg, hypocalcemia, hypokalemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18359968','lexi-content-ref-16849620','lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18359968','lexi-content-ref-16849620','lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diuretic use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Sepsis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent administration of multiple medications (≥2) that prolong the QT interval or medications with drug interactions that increase serum concentrations of QT-prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dermatologic reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dermatologic reactions are usually mild and include maculopapular<b> skin rash </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18627382','lexi-content-ref-19164151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18627382','lexi-content-ref-19164151'])">Ref</a></span>), <b>fixed drug eruption</b> (FDE) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23172357','lexi-content-ref-30417394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23172357','lexi-content-ref-30417394'])">Ref</a></span>), <b>alopecia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7625624','lexi-content-ref-30455235']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7625624','lexi-content-ref-30455235'])">Ref</a></span>) and symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31659833']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31659833'])">Ref</a></span>). Rare reports of severe cutaneous adverse reactions (SCARs) include <b>Stevens-Johnson syndrome</b> (SJS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19548943','lexi-content-ref-18779900']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19548943','lexi-content-ref-18779900'])">Ref</a></span>), <b>toxic epidermal necrolysis</b> (TEN) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23129968','lexi-content-ref-25263725']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23129968','lexi-content-ref-25263725'])">Ref</a></span>), <b>drug reaction with eosinophilia and systemic symptoms </b>(DRESS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27430151','lexi-content-ref-14616149']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27430151','lexi-content-ref-14616149'])">Ref</a></span>), and <b>acute generalized exanthematous pustulosis </b>(AGEP) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11992184','lexi-content-ref-25814733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11992184','lexi-content-ref-25814733'])">Ref</a></span>). Other cutaneous reactions include <b>Sweet’s syndrome</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28891066']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28891066'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic. Maculopapular eruptions, FDE, SDRIFE, and SCARs are T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26553194','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26553194','lexi-content-ref-26339470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed hypersensitivity reactions: Varied. Maculopapular rash usually occurs 5 to 21 days after start of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26553194','lexi-content-ref-19164151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26553194','lexi-content-ref-19164151'])">Ref</a></span>), although can occur after 1 dose, especially in previously sensitized patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18627382','lexi-content-ref-26553194']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18627382','lexi-content-ref-26553194'])">Ref</a></span>). FDE lesions can develop within 15 minutes to 2 days after drug administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23172357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23172357'])">Ref</a></span>). SCARs usually occur 1 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27430151','lexi-content-ref-26120552','lexi-content-ref-19548943','lexi-content-ref-NICE.2014','lexi-content-ref-14616149']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27430151','lexi-content-ref-26120552','lexi-content-ref-19548943','lexi-content-ref-NICE.2014','lexi-content-ref-14616149'])">Ref</a></span>); reexposure may lead to more rapid onset (usually within 1 to 4 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity: Cross-reactivity among oral azole antifungals has not been consistently reported. Possible cross-reactivity between fluconazole and itraconazole has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27430151','lexi-content-ref-11346073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27430151','lexi-content-ref-11346073'])">Ref</a></span>). However, lack of cross-reactivity has been documented between fluconazole and itraconazole, as well as between fluconazole and ketoconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23110686','lexi-content-ref-29294202','lexi-content-ref-14616112','lexi-content-ref-30417394','lexi-content-ref-30829805']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23110686','lexi-content-ref-29294202','lexi-content-ref-14616112','lexi-content-ref-30417394','lexi-content-ref-30829805'])">Ref</a></span>). In addition, no cross-reactivity was noted between fluconazole and voriconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27430151','lexi-content-ref-19164151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27430151','lexi-content-ref-19164151'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Azole antifungals, including fluconazole, may cause <b>hepatotoxicity</b> (ranging from mild and asymptomatic <b>increased serum transaminases</b> to <b>hepatic failure</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27927037','lexi-content-ref-15751740']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27927037','lexi-content-ref-15751740'])">Ref</a></span>). Hepatotoxicity may also occur as part of drug rash eosinophilia with systemic symptoms (DRESS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14616149']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14616149'])">Ref</a></span>). Fluconazole-induced liver injury usually resolves without intervention. If intervention is required, liver injury is generally reversible within ~2 weeks after dose reduction or discontinuation but may recur upon rechallenge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093949','lexi-content-ref-27927037','lexi-content-ref-20308378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093949','lexi-content-ref-27927037','lexi-content-ref-20308378'])">Ref</a></span>). Liver injury is less common with fluconazole than other azoles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26597673']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26597673'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; possibly dose-related but data are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30090793','lexi-content-ref-31762485','lexi-content-ref-Lawson.1998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30090793','lexi-content-ref-31762485','lexi-content-ref-Lawson.1998'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; most cases of hepatotoxicity due to azoles occur within the first month of therapy (but may occur at any time) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093949'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Possibly dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30090793','lexi-content-ref-31762485','lexi-content-ref-Lawson.1998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30090793','lexi-content-ref-31762485','lexi-content-ref-Lawson.1998'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting liver disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26597673','lexi-content-ref-30544724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26597673','lexi-content-ref-30544724'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent hepatotoxic agents and drug interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31093949','lexi-content-ref-27275514']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31093949','lexi-content-ref-27275514'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30090793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30090793'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• HIV infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27275514']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27275514'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity among oral azole antifungals has not been consistently reported in patients with histories of hepatotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27430151','lexi-content-ref-17712772','lexi-content-ref-12684933']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27430151','lexi-content-ref-17712772','lexi-content-ref-12684933'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F171644"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Headache (adults: 2% to 13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (2% to 6%), diarrhea (2% to 3%), dysgeusia (adults: 1%), dyspepsia (adults: 1%), nausea (adults: 4% to 7%; children and adolescents: 2%), vomiting (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (adults: 1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hepatic: Increased serum alkaline phosphatase</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Prolonged QT interval on ECG, torsades de pointes (Poluzzi 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Alsadhan 2002; Di Lernia 2015), alopecia (Pappas 1995), diaphoresis, exfoliative dermatitis, Stevens-Johnson syndrome (Craythorne 2009, Monastirli 2008), Sweet’s syndrome (Adler 2018), toxic epidermal necrolysis (George 2012, Islam 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesterolemia, hypertriglyceridemia, hypokalemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Murakami 1992), leukopenia, neutropenia, thrombocytopenia (Murakami 1992)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis (Joseph 2019), hepatic failure (Gayam 2018), hepatitis (mixed) (Joseph 2019), hepatocellular hepatitis (Joseph 2019), hepatotoxicity (Kyriakidis 2017, Song 2005), increased serum transaminases (Wang 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Neuhaus 1991), angioedema, fixed drug eruption (Nakai 2013, Quint 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Benjamin Lash 2016, Su 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness, fatigue, insomnia, malaise, paresthesia, seizure, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia, myalgia, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F171659"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to fluconazole or any component of the formulation (cross-reaction with other azole antifungal agents may occur, but has not been established; use caution); coadministration with CYP3A4 substrates, which may lead to QTc prolongation (eg, erythromycin, pimozide, quinidine).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F171641"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: May occasionally cause dizziness or seizures; use caution driving or operating machinery.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP 1997; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sucrose: Oral suspension contains sucrose; avoid use in patients with fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency.</p></div>
<div class="block foc drugH1Div" id="F171652"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg (100 mL); 200 mg/100 mL in NaCl 0.9% (100 mL); 400 mg (200 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/50 mL in NaCl 0.9% (50 mL); 200 mg (100 mL [DSC]); 200 mg/100 mL in NaCl 0.9% (100 mL); 400 mg (200 mL); 400 mg/200 mL in NaCl 0.9% (200 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diflucan: 10 mg/mL (35 mL); 40 mg/mL (35 mL) [orange flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (35 mL); 40 mg/mL (35 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diflucan: 50 mg [DSC], 100 mg, 150 mg, 200 mg [contains fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 100 mg, 150 mg, 200 mg</p></div>
<div class="block geq drugH1Div" id="F171637"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F171661"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Fluconazole in Sodium Chloride Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/50 mL 0.9% (per mL): $0.12</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/100 mL 0.9% (per mL): $0.05 - $0.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg/200 mL 0.9% (per mL): $0.03 - $0.42</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Diflucan Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $0.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/mL (per mL): $0.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Fluconazole Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $0.99 - $1.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/mL (per mL): $3.59 - $3.73</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Diflucan Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $73.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $75.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Fluconazole Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $5.57 - $5.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $8.75 - $8.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $13.59 - $14.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $14.32 - $14.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866910"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diflucan: 2-0.9 MG/ML-% (100 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2-0.9 MG/ML-% (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diflucan: 10 mg/mL (35 mL) [contains sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 100 mg, 200 mg</p></div>
<div class="block adip drugH1Div" id="F53566735"><span class="drugH1">Additional Information</span>
<p style="text-indent:-2em;margin-left:2em;">Dosing equivalency suggested by the manufacturer's labeling: </p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients 3 mg/kg = Adults 100 mg </p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients 6 mg/kg = Adults 200 mg </p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients 12 mg/kg = Adults 400 mg 	</p></div>
<div class="block admp drugH1Div" id="F52612849"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer without regard to meals; shake suspension well before use.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Do not use if cloudy or precipitated. Administered by IV infusion over approximately 1 to 2 hours at a rate not to exceed 200 mg/hour. The following infusion times have been described in pediatric patients:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonatal: Loading doses (25 mg/kg) have been infused over 2 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21085048','lexi-content-ref-22627870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21085048','lexi-content-ref-22627870'])">Ref</a></span>); doses ranging from 6 to 12 mg/kg/dose have been infused over 1 to 2 hours including extremely low birth weight neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29744900','lexi-content-ref-27401564','lexi-content-ref-21085048','lexi-content-ref-22627870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29744900','lexi-content-ref-27401564','lexi-content-ref-21085048','lexi-content-ref-22627870'])">Ref</a></span>); a dose of 3 mg/kg/dose may be infused over 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric: Doses up to 8 to 10 mg/kg were infused over 2 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8970221','lexi-content-ref-1593362']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8970221','lexi-content-ref-1593362'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F171656"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Do not use if cloudy or precipitated. Infuse over ≥1 to 2 hours; do not exceed 200 mg/hour.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> May be administered without regard to meals.</p></div>
<div class="block hazard drugH1Div" id="F49132520"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F171672"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet: Store at &lt;30°C (86°F).</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Powder for oral suspension: Store dry powder at &lt;30°C (86°F). Following reconstitution, store at 5°C to 30°C (41°F to 86°F). Discard unused portion after 2 weeks. Do not freeze. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Injection: Store injection in glass at 5°C to 30°C (41°F to 86°F). Store injection in plastic flexible containers with overwrap at 20°C to 25°C (68°F to 77°F). Do not freeze. Do not unwrap unit until ready for use.</p></div>
<div class="block usep drugH1Div" id="F53566950"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of candidiasis (vaginal, oropharyngeal, esophageal, urinary tract infections, peritonitis, pneumonia, and systemic infections); cryptococcal meningitis; antifungal prophylaxis in allogeneic bone marrow transplant recipients (All indications: FDA approved in all ages); has also been used as prophylaxis and treatment of peritonitis and treatment of exit-site and tunnel infections in patients with peritoneal dialysis catheters.</p></div>
<div class="block mst drugH1Div" id="F171739"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fluconazole may be confused with flecainide, FLUoxetine, furosemide, itraconazole, voriconazole</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diflucan may be confused with diclofenac, Diprivan, disulfiram</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Canesten (oral capsules) [Great Britain] may be confused with Canesten brand name for clotrimazole (various dosage forms) [multiple international markets]; Cenestin brand name estrogens (conjugated A/synthetic) [US, Canada] </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F171724"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Inhibits</b> CYP2C19 (strong), CYP2C9 (moderate), CYP3A4 (moderate)</p></div>
<div class="block dri drugH1Div" id="F171646"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Abemaciclib.  Management: Monitor for increased abemaciclib toxicities if combined with moderate CYP3A4 inhibitors. Consider reducing the abemaciclib dose in 50 mg decrements if necessary.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Fluconazole may increase the serum concentration of Abrocitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Acalabrutinib.  Management: Reduce acalabrutinib dose to 100 mg once daily with concurrent use of a moderate CYP3A4 inhibitor. Monitor patient closely for both acalabrutinib response and evidence of adverse effects with any concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ALfentanil.  Management: If use of alfentanil and moderate CYP3A4 inhibitors is necessary, consider dosage reduction of alfentanil until stable drug effects are achieved. Frequently monitor patients for respiratory depression and sedation when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Alfuzosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alitretinoin (Systemic): CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Alitretinoin (Systemic).  Management: Consider reducing the alitretinoin dose to 10 mg when used together with moderate CYP2C9 inhibitors. Monitor for increased alitretinoin effects/toxicities if combined with a moderate CYP2C9 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ALPRAZolam.  Management: Consider alternatives to this combination when possible. If combined, consider an alprazolam dose reduction and monitor for increased alprazolam effects and toxicities (eg, sedation, lethargy).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Amiodarone. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Amiodarone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amitriptyline: May enhance the QTc-prolonging effect of Fluconazole. Fluconazole may increase the serum concentration of Amitriptyline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Apixaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy, indication, or dosage form. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole Lauroxil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Astemizole: Fluconazole may enhance the QTc-prolonging effect of Astemizole. Fluconazole may increase the serum concentration of Astemizole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Atazanavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Atogepant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avacopan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor. Patients receiving such a combination should also be monitored more closely for evidence of adverse effects (eg, hypotension, syncope, priapism).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avapritinib.  Management: Avoid use of moderate CYP3A4 inhibitors with avapritinib. If this combination cannot be avoided, reduce the avapritinib dose to 100 mg daily for the treatment of GIST or to 50 mg daily for the treatment of advanced systemic mastocytosis.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avatrombopag: Fluconazole may increase the serum concentration of Avatrombopag.  Management: For chronic immune thrombocytopenia, reduce initial avatrombopag dose to 20 mg 3 times per week. No dosage reduction needed for patients with chronic liver disease-associated thrombocytopenia using altrombopag prior to a procedure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Axitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barnidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Barnidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belzutifan: CYP2C19 Inhibitors (Strong) may increase the serum concentration of Belzutifan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Blonanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bortezomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosentan: Fluconazole may increase the serum concentration of Bosentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: The brexpiprazole dose should be reduced to 25% of usual if used together with both a moderate CYP3A4 inhibitor and a strong or moderate CYP2D6 inhibitor, or if a moderate CYP3A4 inhibitor is used in a CYP2D6 poor metabolizer.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brigatinib.  Management: Avoid concurrent use of brigatinib with moderate CYP3A4 inhibitors when possible. If such a combination cannot be avoided, reduce the dose of brigatinib by approximately 40% (ie, from 180 mg to 120 mg, from 120 mg to 90 mg, or from 90 mg to 60 mg).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivaracetam: CYP2C19 Inhibitors (Strong) may increase the serum concentration of Brivaracetam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bromocriptine.  Management: The bromocriptine dose should not exceed 1.6 mg daily with use of a moderate CYP3A4 inhibitor. The Cycloset brand specifically recommends this dose limitation, but other bromocriptine products do not make such specific recommendations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic).  Management: Avoid the concomitant use of CYP3A4 inhibitors and oral budesonide. If patients receive both budesonide and CYP3A4 inhibitors, they should be closely monitored for signs and symptoms of corticosteroid excess.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Topical): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of BusPIRone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Capivasertib.  Management: If capivasertib is combined with moderate CYP3A4 inhibitors, reduce the capivasertib dose to 320 mg twice daily for 4 days, followed by 3 days off. Monitor patients closely for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Cariprazine. Specifically, concentrations of didesmethylcariprazine (DDCAR), the primary active metabolite of cariprazine, may increase. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cariprazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carisoprodol: CYP2C19 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Carisoprodol. CYP2C19 Inhibitors (Strong) may increase the serum concentration of Carisoprodol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celecoxib: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Celecoxib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Ceritinib. Ceritinib may enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Ceritinib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilostazol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cilostazol.  Management: Decrease the dose of cilostazol to 50 mg twice daily when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cisapride: Fluconazole may enhance the QTc-prolonging effect of Cisapride. Fluconazole may increase the serum concentration of Cisapride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: Fluconazole may enhance the QTc-prolonging effect of Citalopram. Fluconazole may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with fluconazole, which is a strong CYP2C19 inhibitor. Patients using this combination should be monitored closely for citalopram toxicities, including serotonin syndrome and QT prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Clindamycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloBAZam: CYP2C19 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of CloBAZam. CYP2C19 Inhibitors (Strong) may increase the serum concentration of CloBAZam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel: CYP2C19 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Consider alternatives to this combination whenever possible. If such a combination must be used, monitor patients closely for evidence of a diminished response to clopidogrel.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cobimetinib.  Management: Avoid this combination when possible. If concurrent short term (14 days or less) use cannot be avoided, reduce the cobimetinib dose from 60 mg to 20 mg daily. Avoid concomitant use in patients already receiving reduced cobimetinib doses.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Codeine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Avoidance, dose reduction, or increased monitoring for colchicine toxicity may be needed and will depend on brand, indication for colchicine use, renal/hepatic function, and use of a P-gp inhibitor. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Conivaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Conivaptan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Copanlisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Crizotinib. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Crizotinib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloPHOSphamide: Fluconazole may enhance the adverse/toxic effect of CycloPHOSphamide. Specifically, serum bilirubin and serum creatinine may be increased. Fluconazole may increase the serum concentration of CycloPHOSphamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Fluconazole may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Fluconazole may enhance the anticoagulant effect of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Dabrafenib. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Dabrafenib.  Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and dabrafenib adverse effects when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dapoxetine.  Management: The dose of dapoxetine should be limited to 30 mg per day when used together with a moderate inhibitor of CYP3A4.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Daridorexant.  Management: Limit the daridorexant dose to 25 mg, no more than once per night, when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darifenacin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Darifenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deflazacort: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Deflazacort.  Management: Administer one third of the recommended deflazacort dose when used together with a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DexAMETHasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexlansoprazole: CYP2C19 Inhibitors (Strong) may increase the serum concentration of Dexlansoprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP2C19 Inhibitors (Strong) may increase the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Antifungal Agents (Azole Derivatives, Systemic) may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diclofenac (Systemic): CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Diclofenac (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DilTIAZem: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DilTIAZem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOCEtaxel: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DOCEtaxel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Domperidone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Dronedarone. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Dronedarone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ebastine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ebastine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elbasvir and Grazoprevir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eletriptan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor.  Management: When combined with moderate CYP3A4 inhibitors, elexacaftor/tezacaftor/ivacaftor should be given in the morning, every other day. Ivacaftor alone should be given in the morning, every other day on alternate days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Reduce eliglustat dose to 84 mg daily in CYP2D6 EMs when used with moderate CYP3A4 inhibitors. Avoid use of moderate CYP3A4 inhibitors in CYP2D6 IMs or PMs. Use in CYP2D6 EMs or IMs also taking strong or moderate CYP2D6 inhibitors is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Encorafenib. Management: Avoid use of encorafenib and moderate CYP3A4 inhibitors when possible. If combined, decrease encorafenib dose from 450 mg to 225 mg; 300 mg to 150 mg; and 225 mg or 150 mg to 75 mg. Monitor closely for QT interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Entrectinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: If coadministered with moderate CYP3A4 inhibitors, the max dose of eplerenone is 25 mg daily if used for heart failure; if used for hypertension initiate eplerenone 25 mg daily, titrate to max 25 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Erdafitinib.  Management: Avoid concomitant use of erdafitinib and moderate CYP2C9 inhibitors when possible. If combined, monitor closely for erdafitinib adverse reactions and consider dose modifications accordingly.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Erlotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): Fluconazole may enhance the QTc-prolonging effect of Erythromycin (Systemic). Fluconazole may increase the serum concentration of Erythromycin (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: May enhance the QTc-prolonging effect of Fluconazole. Fluconazole may increase the serum concentration of Escitalopram.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eszopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eszopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etizolam: CYP2C19 Inhibitors (Strong) may increase the serum concentration of Etizolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: Fluconazole may increase the serum concentration of Etrasimod. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP2C19 Inhibitors (Strong) may increase the serum concentration of Etravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fedratinib: Fluconazole may increase the serum concentration of Fedratinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Felodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Consider fentanyl dose reductions when combined with a moderate CYP3A4 inhibitor. Monitor for respiratory depression and sedation. Upon discontinuation of a CYP3A4 inhibitor, consider a fentanyl dose increase; monitor for signs and symptoms of withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Fexinidazole. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may decrease serum concentrations of the active metabolite(s) of Fexinidazole.  Management: Consider alternatives to this combination. If combined, monitor for QT interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QT prolongation may be at even higher risk. Also monitor for reduced fexinidazole efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Flibanserin.  Management: Use of flibanserin with moderate CYP3A4 inhibitors is contraindicated. If starting flibanserin, start 2 weeks after the last dose of the CYP3A4 inhibitor. If starting a CYP3A4 inhibitor, start 2 days after the last dose of flibanserin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flurbiprofen (Systemic): CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Flurbiprofen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluticasone (Nasal): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fluticasone (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fluticasone (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluvastatin: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Fluvastatin.  Management: Fluvastatin should be used at the lowest effective dose and should not exceed 20 mg twice daily when combined with moderate CYP2C9 inhibitors. Avoid coadministration of fluvastatin extended-release tablets with moderate CYP2C9 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fosamprenavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fosaprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: CYP2C19 Inhibitors (Strong) may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Gepirone.  Management: Reduce the gepirone dose by 50% if combined with moderate CYP3A4 inhibitors. Monitor for QTc interval prolongation with combined use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Glasdegib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of GuanFACINE.  Management: Reduce the extended-release guanfacine dose 50% when combined with a moderate CYP3A4 inhibitor. Monitor for increased guanfacine toxicities when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Haloperidol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ibrutinib.  Management: When treating B-cell malignancies, decrease ibrutinib to 280 mg daily when combined with moderate CYP3A4 inhibitors. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibuprofen: Fluconazole may increase the serum concentration of Ibuprofen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Iloperidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, the serum concentration of SN-38 may be increased. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Irinotecan Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inhibitors (Moderate) may increase isavuconazole serum concentrations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Isradipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Itraconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Ivacaftor dose reductions may be required; consult full drug interaction monograph content for age- and weight-specific dosage recommendations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivosidenib: May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Ivosidenib. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lansoprazole: CYP2C19 Inhibitors (Strong) may increase the serum concentration of Lansoprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Larotrectinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lefamulin.  Management: Monitor for lefamulin adverse effects during coadministration of lefamulin tablets with moderate CYP3A4 inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Leniolisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lercanidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomilnacipran: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levomilnacipran. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Lidocaine (Systemic). Specifically, concentrations of monoethylglycinexylidide (MEGX) may be increased. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lonafarnib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lopinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorlatinib: Fluconazole may increase the serum concentration of Lorlatinib.  Management: Avoid use of lorlatinib with fluconazole whenever possible. If the combination cannot be avoided, reduce the lorlatinib dose from 100 mg once daily to 75 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lornoxicam: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Lornoxicam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Losartan: CYP2C9 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Losartan. CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Losartan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lovastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lumateperone.  Management: Limit the lumateperone dose to 21 mg once daily when used with a moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: US labeling recommends reducing lurasidone dose by 50% with a moderate CYP3A4 inhibitor and initiating 20 mg/day, max 80 mg/day. Some non-US labels recommend initiating lurasidone 20 mg/day, max 40 mg/day. Avoid concurrent use of grapefruit products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurbinectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurbinectedin.  Management: Avoid concomitant use of lurbinectedin and moderate CYP3A4 inhibitors when possible. If combined, consider a lurbinectedin dose reduction as clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: Fluconazole may increase the serum concentration of Macitentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Manidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Manidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Maraviroc. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP2C19 Inhibitors (Strong) may increase the serum concentration of Mavacamten. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meloxicam: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Meloxicam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Methadone. Management: Consider alternatives to this drug combination. If combined, monitor for increased methadone toxicities (eg, respiratory depression, QTc interval prolongation). Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of MethylPREDNISolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methysergide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Methysergide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Midazolam.  Management: Avoid concomitant use of nasal midazolam and moderate CYP3A4 inhibitors. Consider alternatives to use with oral midazolam whenever possible and consider using lower midazolam doses. Monitor patients for sedation and respiratory depression if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of MiFEPRIStone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mitapivat.  Management: When coadministered with moderate CYP3A4 inhibitors, doses of mitapivat should not exceed 20 mg twice daily. Additionally, patients should be monitored for changes in hemoglobin response and increased mitapivat adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mizolastine: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Mizolastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Mobocertinib. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase serum concentrations of the active metabolite(s) of Mobocertinib. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Mobocertinib.  Management: Avoid use of QT prolonging moderate CYP3A4 inhibitors with mobocertinib when possible. If combined, the mobocertinib dose should be reduced by approximately 50% (ie, from 160 mg to 80 mg, 120 mg to 40 mg, or 80 mg to 40 mg). Monitor QTc interval closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Moclobemide: CYP2C19 Inhibitors (Strong) may increase the serum concentration of Moclobemide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalfurafine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nalfurafine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naloxegol.  Management: The use of naloxegol and moderate CYP3A4 inhibitors should be avoided. If concurrent use is unavoidable, reduce naloxegol dose to 12.5 mg once daily and monitor for signs of opiate withdrawal (eg, hyperhidrosis, chills, diarrhea, anxiety, irritability).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nateglinide: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Nateglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: CYP2C19 Inhibitors (Strong) may increase the serum concentration of Nelfinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Neratinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nevirapine: Fluconazole may increase the serum concentration of Nevirapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NIFEdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nitrendipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olaparib.  Management: Avoid use of moderate CYP3A4 inhibitors with olaparib, if possible. If such concurrent use cannot be avoided, the dose of olaparib tablets should be reduced to 150 mg twice daily and the dose of olaparib capsules should be reduced to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Omaveloxolone.  Management: Avoid this combination if possible. If coadministration is required, decrease the omaveloxolone dose to 100 mg daily and monitor closely for adverse reactions. If adverse reactions occur, decrease omaveloxolone to 50 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omeprazole: CYP2C19 Inhibitors (Strong) may increase the serum concentration of Omeprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ospemifene: Fluconazole may increase the serum concentration of Ospemifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite Oxymorphone may also be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Palbociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Palovarotene.  Management: Avoid concomitant use of palovarotene and moderate CYP3A4 inhibitors when possible. If combined, decrease palovarotene dose by 50% as described in the full interaction monograph. Monitor for palovarotene toxicities when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Panobinostat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Panobinostat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Parecoxib: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Parecoxib. Specifically, serum concentrations of the active moiety valdecoxib may be increased.  Management: Use the lowest effective dose of parecoxib and consider a dose reduction in patients taking moderate CYP2C9 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of PAZOPanib. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of PAZOPanib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pemigatinib.  Management: If combined use cannot be avoided, reduce the pemigatinib dose from 13.5 mg daily to 9 mg daily, or from 9 mg daily to 4.5 mg daily. Resume prior pemigatinib dose after stopping the moderate inhibitor once 3 half-lives of the inhibitor has passed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pexidartinib.  Management: If combined use cannot be avoided, pexidartinib dose should be reduced. For the 125 mg capsules: reduce pexidartinib doses of 500 mg or 375 mg daily to 125 mg twice daily. Reduce pexidartinib 250 mg daily to 125 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimavanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pirtobrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PONATinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazepam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Prazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Praziquantel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Proguanil: CYP2C19 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Proguanil. CYP2C19 Inhibitors (Strong) may increase the serum concentration of Proguanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IA Antiarrhythmics (Highest Risk): Fluconazole may enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics (Highest Risk).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class III Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Class III Antiarrhythmics (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Highest Risk): May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Kinase Inhibitors (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Kinase Inhibitors (Moderate Risk). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Highest Risk): Fluconazole may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Fluconazole.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Miscellaneous Agents (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): Fluconazole may enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk): May enhance the QTc-prolonging effect of Fluconazole. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): Fluconazole may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QUEtiapine. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QUEtiapine.  Management: Monitor for increased quetiapine toxicities including QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: Fluconazole may enhance the QTc-prolonging effect of QuiNIDine. Fluconazole may increase the serum concentration of QuiNIDine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinidine (Non-Therapeutic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Quinidine (Non-Therapeutic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramelteon: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors. Monitor for increased ranolazine effects and toxicities during concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Red Yeast Rice: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Red Yeast Rice. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Regorafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rifabutin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Fluconazole. Fluconazole may increase the serum concentration of RifAMPin. Management: Consider increasing the dose of fluconazole when used concurrently with rifampin. When combined, monitor for both reduced clinical efficacy of fluconazole and increased rifampin toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of Fluconazole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rimegepant.  Management: If taking rimegepant for the acute treatment of migraine, avoid a second dose of rimegepant within 48 hours when used concomitantly with moderate CYP3A4 inhibitors. No dose adjustment needed if using rimegepant for prevention of episodic migraine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of RisperiDONE.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ritonavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rivaroxaban. This warning is more specifically for drugs that are inhibitors of both CYP3A4 and P-glycoprotein.  For erythromycin, refer to more specific erythromycin-rivaroxaban monograph recommendations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast-Containing Products: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Roflumilast-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rupatadine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rupatadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Systemic): Fluconazole may increase the serum concentration of Ruxolitinib (Systemic).  Management: Avoid fluconazole doses over 200 mg/day in combination with ruxolitinib. Dose adjustments are required in some circumstances. See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saccharomyces boulardii: Antifungal Agents (Systemic and Oral [Non-Absorbable]) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SAXagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SAXagliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Selpercatinib. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Selpercatinib.  Management: Avoid combination if possible. If use is necessary, reduce selpercatinib dose as follows: from 120mg twice/day to 80mg twice/day, or from 160mg twice/day to 120mg twice/day. Monitor QT interval more closely for QTc interval prolongation and arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Selumetinib.  Management: Avoid concomitant use when possible. If combined, selumetinib dose reductions are recommended and vary based on body surface area and selumetinib dose. For details, see the full drug interaction monograph or selumetinib prescribing information.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Sertindole. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Sertindole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Silodosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Simvastatin. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Fluconazole may increase the serum concentration of Siponimod. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): Fluconazole may increase the serum concentration of Sirolimus (Conventional).  Management: Monitor for increased serum concentrations of sirolimus if combined with fluconazole. Lower initial sirolimus doses or sirolimus dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solifenacin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Solifenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sonidegib.  Management: Avoid concomitant use of sonidegib and moderate CYP3A4 inhibitors when possible.  When concomitant use cannot be avoided, limit CYP3A4 inhibitor use to less than 14 days and monitor for sonidegib toxicity (particularly musculoskeletal adverse reactions).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sparsentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SUFentanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of SUNItinib. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of SUNItinib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Suvorexant.  Management: The recommended dose of suvorexant is 5 mg daily in patients receiving a moderate CYP3A4 inhibitor. The dose can be increased to 10 mg daily (maximum dose) if necessary for efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Fluconazole may increase the serum concentration of Tacrolimus (Systemic).  Management: Monitor tacrolimus concentrations closely and adjust oral tacrolimus dose as necessary when concomitantly administered with fluconazole. Reduced doses of tacrolimus will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tadalafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamsulosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tazemetostat.  Management: Avoid when possible. If combined, reduce tazemetostat dose from 800 mg twice daily to 400 mg twice daily, from 600 mg twice daily to 400 mg in AM and 200 mg in PM, or from 400 mg twice daily to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, concentrations of sirolimus may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terfenadine: Fluconazole may enhance the QTc-prolonging effect of Terfenadine. Fluconazole may increase the serum concentration of Terfenadine.  Management: Concomitant use of fluconazole at doses of 400 mg/day or greater and terfenadine is contraindicated and should be avoided. If lower doses of fluconazole and terfenadine are combined, monitor patients for QT-prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol and Cannabidiol. Specifically, concentrations of tetrahydrocannabinol may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol and Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tezacaftor and Ivacaftor.  Management: If combined with moderate CYP3A4 inhibitors, give tezacaftor/ivacaftor in the morning, every other day; give ivacaftor in the morning, every other day on alternate days. Tezacaftor/ivacaftor dose depends on age and weight; see full Lexi-Interact monograph<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Fluconazole may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Thiotepa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: Fluconazole may increase the serum concentration of Tipranavir.  Management: Limit fluconazole adult maximum dose to 200 mg/day in patients treated with tipranavir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Fluconazole may increase the serum concentration of Tofacitinib.  Management: Tofacitinib dose reductions are recommended when combined with fluconazole. Recommended dose adjustments vary by tofacitinib formulation and therapeutic indication. See full Lexi Interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolterodine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolterodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.  Management: Avoid this combination with Samsca brand of tolvaptan. Reduce dose for Jynarque brand: 90 mg AM and 30 mg PM, reduce to 45 mg AM and 15 mg PM; 60 mg AM and 30 mg PM, reduce to 30 mg AM and 15 mg PM; 45 mg AM and 15 mg PM, reduce to 15 mg AM and PM.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Torsemide: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Torsemide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Trabectedin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of TraMADol. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of TraZODone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tretinoin (Systemic): Fluconazole may increase the serum concentration of Tretinoin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Triazolam.  Management: Consider triazolam dose reduction in patients receiving concomitant moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 50 mg and avoid a second dose for 24 hours when used with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Udenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Udenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ulipristal. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Valbenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vamorolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vamorolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vardenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vardenafil.  Management: Limit Levitra (vardenafil) dose to a single 5 mg dose within a 24-hour period if combined with moderate CYP3A4 inhibitors. Avoid concomitant use of Staxyn (vardenafil) and moderate CYP3A4 inhibitors. Combined use is contraindicated outside of the US.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring concomitant treatment with moderate CYP3A4 inhibitors. Resume the previous venetoclax dose 2 to 3 days after discontinuation of moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Verapamil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinBLAStine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of VinBLAStine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vindesine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vindesine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinflunine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Vinflunine. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vinflunine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Fluconazole may increase the serum concentration of Vitamin K Antagonists.  Management: Consider alternatives when possible. If combined, consider reducing the vitamin K antagonist dose by 10% to 20% if combined with fluconazole. Monitor for increased anticoagulant effects (ie, increased INR, bleeding) to guide further dose adjustments.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Voclosporin.  Management: Decrease the voclosporin dose to 15.8 mg in the morning and 7.9 mg in the evening when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vorapaxar. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: Fluconazole may enhance the QTc-prolonging effect of Voriconazole. Fluconazole may increase the serum concentration of Voriconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zanubrutinib.  Management: Decrease the zanubrutinib dose to 80 mg twice daily during coadministration with a moderate CYP3A4 inhibitor. Further dose adjustments may be required for zanubrutinib toxicities, refer to prescribing information for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuranolone. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F52771768"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Based on human data, in utero exposure to high doses of fluconazole may cause fetal harm. According to the manufacturer, patients who may become pregnant and who are taking higher doses (≥400 mg/day) should use effective contraception during therapy and for ~1 week after the final fluconazole dose.</p></div>
<div class="block pri drugH1Div" id="F171662"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on human data, in utero exposure to high doses of fluconazole may cause fetal harm. Following exposure during the first trimester, malformations have been noted in humans when maternal fluconazole was used in higher doses (≥400 mg/day). Abnormalities reported include brachycephaly, abnormal facies, abnormal calvarial development, cleft palate, femoral bowing, thin ribs and long bones, arthrogryposis, and congenital heart disease. Fetal outcomes following exposure to lower doses is less clear and additional study is needed to confirm an association between maternal use of low dose fluconazole and an increased risk of birth defects. However, epidemiological studies of fluconazole ≤150 mg as a single dose or repeated doses in the first trimester suggest a potential risk of spontaneous abortion and malformations (Budani 2021; Diflucan [fluconazole oral] prescribing information).</p>
<p style="text-indent:0em;margin-top:2em;">Oral fluconazole for the treatment of vaginal candidiasis is not recommended during pregnancy. Topical therapy for oral or vaginal candidiasis is recommended in pregnant patients (HHS [OI adult] 2023; Workowski [CDC 2021]). Secondary prophylaxis or chronic maintenance therapy using oral or IV fluconazole should not be initiated during pregnancy for esophageal, oropharyngeal, or vaginal candidiasis; fluconazole should be discontinued if pregnancy occurs during therapy (HHS [OI adult] 2023). Fluconazole is not the treatment of choice for invasive candidiasis in pregnant patients (IDSA [Pappas 2016]). Fluconazole may be used for the treatment of cryptococcosis or coccidioidomycosis after the first trimester if otherwise appropriate (HHS [OI adult] 2023; IDSA [Galgiani 2016]; Pastick 2020).</p></div>
<div class="block mopp drugH1Div" id="F53566936"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Periodic liver function (AST, ALT, alkaline phosphatase), renal function tests, serum potassium, CBC with differential and platelet count; conjugated bilirubin in neonates (Egunsola 2013)</p></div>
<div class="block pha drugH1Div" id="F171640"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Interferes with fungal cytochrome P450 activity (lanosterol 14-α-demethylase), decreasing ergosterol synthesis (principal sterol in fungal cell membrane) and inhibiting cell membrane formation</p></div>
<div class="block phk drugH1Div" id="F171658"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Well absorbed; food does not affect extent of absorption.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely throughout the body with good penetration into CSF, eye, peritoneal fluid, sputum, skin, and urine.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm and term neonates: ~1 L/kg (Hwang 2017).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥5 years and Adolescents ≤15 years: Mean range: 0.722 to 1.069 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: ~0.6 L/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Relative diffusion blood into CSF: Adequate with or without inflammation (exceeds usual MICs).</p>
<p style="text-indent:-2em;margin-left:4em;">CSF:blood level ratio: Normal meninges: 50% to 90%; Inflamed meninges: ~80%.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma: 11% to 12%.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: &gt;90%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm neonates: GA 26 to 29 weeks:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;36 hours PNA: 73.6 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">~7 days PNA: 53.2 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">~13 days PNA: 46.4 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥9 months, Children, and Adolescents ≤13 years (single dose, oral): Mean range: 19.5 to 25 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents ≤15 years (multiple dose, IV): Mean range: 15.2 to 17.6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~30 hours (range: 20 to 50 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Older Adults ≥65 years: 46.2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: 1 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (80% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F51192580"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Pharmacokinetics are markedly affected; there is an inverse relationship between half-life and creatinine clearance.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F171665"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Exomax | Flucand | Flucifem | Unizol</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Antimicon | Cansis | Farmiclox | Femixol | Flucoderm | Flucoginkan | Flucolaf | Fluconal | Fluconazol denver farma | Fluconazol fabra | Fluconazol Ilab | Fluconazol jayor | Fluconazol lafedar | Fluconazol Norgreen | Fluconazol Northia | Fluconazol richet | Fluconazol rivero | Fluconazol roux ocefa | Fluconazol vannier | Flupec | Fluzol | Fungocina | Fungototal | Klonarizol | Klonazol | Labsazol Novo | Mutum | Nifurtox | Nimic | Nipar | Ponaris | Triflucan</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fluconazol b braun | Fluconazol hikma | Fluconazol ratiopharm | Fluconazol sandoz</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Aspen fluconazole | Diflucan | Fluconazole alphapharm | Fluconazole Claris | Fluconazole hexal | Fluconazole sandoz</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Anfasil | Canazole | Candid | Diflu | F zol | Fluact | Flubest | Flucoder | Fluconal | Flucostin | Flugal | Flumyc | Flunac | Flunazol | Flunol | Fluvin OD | Fluzo | Fluzole | Fungata | Fungitrol | Iluca | Leucoder | Lucan R | Mycoder | Nispore | Nogal | Olif | Omastin | Oraf | Xeroder</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fluconazol | Fluconazol Docpharma | Fluconazole b.braun | Fluconazole mylan | Fluconazole Teva</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Fairzol | Flucoas | Flucomyc | Flugen | Flukas | Mukestat</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Diflazon | Diflucan | Exomax | Fungocap | Fungolon | Mycosyst</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Exomax | Flucanol | Flucazol | Fluconazol | Flucozen | Flunal | Fluxozol | Fresolcan | Fungiciden | Hiconazol | Pantec | Triazol | Zolstatin | Zoltec | Zoltren</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fluconazol Baxter | Fluconazol Labatec | Fluconazol Mepha | Fluconazol sandoz | Fluconazol teva</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Flucomyc | Fluconazole kabi | Flukas | Mukestat | Odaft | Ronzole | Triflucan | Zocon</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Exomax | Plusgin | Tavor</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bin li | Chen ze | Diflucan | Fiuconazole | Flucoric | Fu qiang | Hao kang | Lai kang | Lai pu luo kang | Qian de | Shuai ke feng | Syscan | Tianfang li xing | Xi xin shu | Yi li kang | Yi qi fu</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ciplaflucon | Diflucan | Exomax | Flucomicon | Fluconazol | Fluconazol mk | Fujisen | Funex | Fuzolpauly | Nirfluco | Tavor | Tergonil</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Diflazon | Diflucan | Fluconazol | Fluconazol ardez | Fluconazol kabi | Fluconazol Redibag Baxter | Fluconazol teva | Fluconazole B Braun | Fluconazole vitabalans | Mycomax | Mycosyst</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fluconazol | Fluconazol b braun | Fluconazol claris | Fluconazol Hexal | Fluconazol hikma | Fluconazol i.v. DeltaSelect | Fluconazol kabi | Fluconazol lyomark | Fluconazol Pharmore | Fluconazol ratiopharm</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Antimicon | Baten | Flucobac | Fluconazol | Fluconazol Alfa | Fluconazol Feltrex | Flumac | Forcan | Fujisen | Fungostat | Furex | Loitin | Luxazole</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Baten | Diflucan | Flucocid | Flucomicon | Fluconazol | Fluconazol nifa | Tavor</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Diflazon | Diflucan | Fluconazole baxter | Fluconazole Claris | Fluconazole vitabalans | Mycosyst</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Flucand | Fluctobar</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Citiges | Diflucan | Fluconazol b. braun | Fluconazol Combino pharm | Fluconazol Farmages | Fluconazol Ges | Fluconazol kabi | Fluconazol Kern | Fluconazol normon | Fluconazol teva | Fluconazol Tevagen | Lavisa | Loitin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fluconaz Fresenius Kabi | Fluconazol Copyfarm | Fluconazol vitabalans | Fluconazole B Braun | Fluconazole Claris</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fluconazole aguettant | Fluconazole Arrow | Fluconazole Biogaran | Fluconazole Dakota pharm | Fluconazole EG | Fluconazole kabi | Fluconazole macopharma | Fluconazole mylan | Fluconazole panpharma | Fluconazole pfizer | Fluconazole Qualimed | Fluconazole ratiopharm | Fluconazole Redibag | Fluconazole sandoz | Fluconazole Teva | Fluconazole Zentiva | Triflucan</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fluconazole Genus | Fluconazole kent</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Flucanid | Flucodrug | Fluconazole/b.braun | Fluconazole/Baxter | Fluconazole/kabi | Fluconazole/medicus | Fluconazole/noridem | Fluconazole/Teva | Flucovein | Fungustatin | Hadlinol | Stabilanol | Tierlite</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fluzac</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Flukonazol Kabi</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fluconazole kabi | Fluconazole Teva | Fluconazole vitabalans | Mycosyst</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fludis | Fluxar | Fungoz | Funzela | Govazol</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Flucol</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Diflucan</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acroflu | Adcon | Af | Afflu | Alflucoz | Alicon | Antif | Atcan | Candigyl | Canzika | Cona | Concize | Cozen | Depxit | Epicon | F one | F-con | F-conaz | Fabizol | Fasicon | Faze | Fazol | Fcn | Fcz | Flc | Floroxan | Flucalup | Flucan | Flucare | Flucaz | Flucess | Fluco c | Flucofit | Flucolab | Flucon | Fluconex | Flucoric | Flucos | Flucoside | Flucostat | Flucovax | Fludar | Fluent | Flufung | Flugal | Flugee | Fluka | Flukem | Fluless | Flumed | Fluna | Flunaz | Fluneon | Flunova | Fluoc | Fluol | Fluomax | Flupack | Flurmis | Flustan | Flustate | Flusys | Flusyst | Flutas | Flutrox | Flutuff | Fluza | Fluzant | Fluzole | Fluzon | Fole | Forcan | Forcan plus | Fresocan | Fucan | Fucon | Funasis | Funaz | Fune | Fungal-f | Fungard | Fungary | Fungiban | Fungicip | Fungicon | Fungid | Fungikem o | Fungin | Fungipar | Fungisan F | Fungisure | Fungo | Funspor | Fusys | Futiza | Fuzol | Geoflu | Glenflu | Gocan | Halnaz | Hilzol | Hinzole | Ican | Kon | Kozole | Lifecon | Lodo | Logican | Lozic | Mkonazole | Monocan | Myconorm-f | Mycopar | Mycosure | Myzole | Natcon | Nazole | Ntfung | Nucan | Nucon | Nuconazole | Nuflucon | Nuforce | Odcan | Odicon | Onecan | Oniza | Reflu | Rocflu | Saf-f | Scasis | Solcan | Staflu | Stanflu | Stefazole | Surfaz O | Syncozol | Syscan | Sysflu | Tob | Triben-f | Trucand | Uco | Ultican | Vilzole | Vinfem | Xenofun | Zecon | Zefun | Zocon | Zody</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Biozolene | Diflucan | Elazor | Exomax | Fluconazolo | Fluconazolo aristo | Fluconazolo Bbu | Fluconazolo kabi | Fluconazolo keironpharma | Fluconazolo ratiopharm | Fluconazolo Sandoz</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Flucand | Flucover</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Alnazol | Biskarz | Diflucan | Flanos | Flucard | Fluconamerck | Fluconarl | Fluconazole f | Fluconazole nm | Fluconazon | Flurabin | Fluzole | Fulkazil | Fultanzol | Fultanzol chemiphar | Furuzonar | Mycosyst | Nicoazolin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Candinil | Candizole | Criptocan | Diconazol | Diflucan | Fcn | Fcozole | Flucanol | Flucimet | Fluconazole amring | Flugal | Flutrox | Fluzon | Funasis | Gv fluc | Odaft | Omastin | Syscan | Unizol | Zolecon | Zolocan | Zorcan</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Canazole | Dicazol | Diflucan | Difnazol | Difucozole | Dimoorocan | Filuco | Flocan | Flucan | Fluco | Flucopam | Flucozole | Flukan | Fluna | Flunal | Flutecan | Fluzin | Fluzone | Fuluconal | Funazolem | Furacan | Furonal | Furunal | Ilyangbio fluconazole | Kanazol | Liconazole | Neoconal | Oneflu | Plunazole | Prunazol | Selfnazole | Tinazole | Woongconazole</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Myxen</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Flocazole | Flucand | Flucolab | Fluconazole mylan | Flucozal | Fluzan | Funzol | Myxen | Stabilanol | Unizol</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fluconazol B.Braun | Fluconazole Claris | Fluconazole ibe | Fluconazole vitabalans | Mycosyst</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Diflucan</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fluconazol | Fluconazole Claris | Fluconazole vitabalans | Forcan | Mycosyst</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fluconazole Gt | Fongican | Triflucan</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Afungil | Canfrezol | Diflucan | Exomax | Fluconazol | Flucoxan | Mavinazol | Zoflutec</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo fluconazole | Diflucan | Fcn | Flucon | Fluconazole kabi | Fluconol | Odaft | Zocon | Zolstan</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Fluconazole mylan | Flurekzol | Fungiban | Glozole | Johnbee fluconazole | Paxterex fluconazole | Rumconazole</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fluconazol | Fluconazol hikma | Fluconazol sandoz</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fluconazol | Fluconazol B.Braun | Fluconazol claris | Fluconazol Farmaplus</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fluconazole baxter</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fcn-150 | Flucanol | Flucomicon | Flucomycin | Fluconazol | Flucostat | Flucozol | Mutum | Sisfluzol | Zolstan</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Dyzolor | Exomax | Fleozol | Flucopharm | Fungican | Funzela | Mycozole | Odaft | Zoleshot</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Abiflu | Adcon | Afcon | Alfazole | Astepar | Bactocan | Caratin | Cozil | Derocon | Difazon | Diflucan | Fcozole | Flick | Flisk | Flu-z | Flucal | Flucib | Flucom | Flucon | Flucowel | Flufung | Flukazol | Fluren | Fonaz | Fungvel | Fuzon | Gt zole | Jascon | Leucon | Lunim | Mycocin | Myxen | Na zole | No fung | Notocan | Oakzole | Renflu | Simfluc | Trican | Triflucan | Zefung</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fluconazole b. braun | Fluconazole kabi | Fluconazole polfarmex | Fluconazole Redibag | Flucorta | Flumycon | Mycomax | Mycosyst</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Diflucan</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fluconazol | Fluconazol farmoz | Fluconazol generis | Fluconazol hikma | Fluconazol kabi | Fluconazol labesfal | Fluconazol sidefarma | Reforce</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Fluconazol bergamo | Fluconazol icu vita | Fluconazol interlabo | Fluconazol prosalud | Mycotix | Nifurtox | Spirolac</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Candeur | Candivast | Diflucan | Duracan | Exomax | Flucand | Flucazol | Flucoral | Flucoric | Flunazol | Fluzole | Fukole | Fungimid | Funzol | Oramax</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Diflazon | Diflucan | Fluconazol infomed | Fluconazol kabi | Fluconazol zentiva | Fluconazole b. braun</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Binnoflunazol | Diflazon | Diflucan | Flucomabol | Fluconazole akti | Fluconazole elfa | Fluconazole kabi | Flucorus | Flucostat | Flucozan | Forcan | Forkan | Medoflucon | Mycoflucan | Mycomax | Myconyl | Mycosist | Mycosyst | Procanazol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Candeur | Diflucan | Flucand | Flukas | Pms-fluconazole</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fluconazol Copyfarm | Fluconazol Fresenius | Fluconazol Hexal | Fluconazol Nycomed | Fluconazol Villerton | Fluconazole B Braun | Fluconazole baxter</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Exomax</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Diflazon | Diflucan | Fluconazole Pliva | Flukonazol | Flukonazol B Braun | Flukonazol Claris | Flukonazol vitabalans</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fluconazol | Fluconazol kabi | Fluconazole b. braun | Fluconazole vitabalans | Mycomax | Mycosyst</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Zooflucan</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Flucozole</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Flucand | Flukas | Triflucan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Candisept | Flucofex | Fluject | Flukol | Flukopol | Fungan | Lumen | Selfleks flukosel | Triflucan | Zofunol</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Flucon | Fluene | Fluzole | Fukole | Genazole</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Apo fluconazole | Diflazon | Diflucan | Fluconaz | Fluconazol | Fluconazol Apotex | Fluzak | Forcan | Fucis | Fusys | Mycomax | Mycosist</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Flucan | Flucanir | Flucazol | Flucolife | Fluzol | Unizol | Zocon</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Fluconazol | Fluconazol Icu | Fungiciden | Fungocina | Mutum | Periplum | Sistemic | Triflucam</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Albesin | Diflucan | Exomax | Fluconazol | Fluziwell | Fugin | Fungomax | Zolstan</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aspen fluconazole | Bio fluconazole | Diflucan | Exomax | Fluconazole fresenius | Fluzol | Glenmark fluconazole | Zucan</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Diflucan | Fcn | Flucanol | Flucolife | Flugen | Fluzon | Ultican | Zolmed</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Flucanol | Fluken</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP40.1">
<a name="USP40.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28891066">
<a name="28891066"></a>Adler NR, Lin MJ, Cameron R, Gin D. Fluconazole-induced Sweet's syndrome: A novel association. <i>Australas J Dermatol</i>. 2018;59(2):e160-e161. doi:10.1111/ajd.12709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/28891066/pubmed" id="28891066" target="_blank">28891066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9332650">
<a name="9332650"></a>Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. <i>Am J Med Genet.</i> 1997;72(3):253-256.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/9332650/pubmed" id="9332650" target="_blank">9332650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27550344">
<a name="27550344"></a>Alobaid AS, Wallis SC, Jarrett P, et al. Effect of obesity on the population pharmacokinetics of fluconazole in critically ill patients. <i>Antimicrob Agents Chemother</i>. 2016;60(11):6550-6557. doi:10.1128/AAC.01088-16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/27550344/pubmed" id="27550344" target="_blank">27550344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11992184">
<a name="11992184"></a>Alsadhan A, Taher M, Krol A. Acute generalized exanthematous pustulosis induced by oral fluconazole. <i>J Cutan Med Surg</i>. 2002;6(2):122-124. doi:10.1007/s10227-001-0035-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/11992184/pubmed" id="11992184" target="_blank">11992184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25409999">
<a name="25409999"></a>Ameen M, Lear JT, Madan V, Mohd Mustapa MF, Richardson M. British Association of Dermatologists' guidelines for the management of onychomycosis 2014. <i>Br J Dermatol</i>. 2014;171(5):937-958. doi:10.1111/bjd.13358<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/25409999/pubmed" id="25409999" target="_blank">25409999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2">
<a name="AAP.2"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ampel.2018">
<a name="Ampel.2018"></a>Ampel NM, Blair JE. Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 27, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7622915">
<a name="7622915"></a>Anaissie EJ, Kontoyiannis DP, Huls C, et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. <i>J Infect Dis</i>. 1995;172(2):599-602. doi:10.1093/infdis/172.2.599<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/7622915/pubmed" id="7622915" target="_blank">7622915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. </i>5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24379304">
<a name="24379304"></a>Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. <i>J Antimicrob Chemother</i>. 2014;69(5):1162-1176. doi:10.1093/jac/dkt508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/24379304/pubmed" id="24379304" target="_blank">24379304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31155770">
<a name="31155770"></a>Aslam S, Rotstein C; AST Infectious Disease Community of Practice. Candida infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13623. doi:10.1111/ctr.13623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/31155770/pubmed" id="31155770" target="_blank">31155770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30900315">
<a name="30900315"></a>Baddley JW, Forrest GN; AST Infectious Diseases Community of Practice. Cryptococcosis in solid organ transplantation-guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13543. doi:10.1111/ctr.13543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/30900315/pubmed" id="30900315" target="_blank">30900315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23110686">
<a name="23110686"></a>Bavbek S, Yilmaz İ, Sözener ZÇ. Fixed drug eruption caused by ornidazole and fluconazole but not isoconazole, itraconazole, ketoconazole and metronidazole. <i>J Dermatol</i>. 2013;40(2):134-135. doi:10.1111/1346-8138.12023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/23110686/pubmed" id="23110686" target="_blank">23110686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31093949">
<a name="31093949"></a>Benitez LL, Carver PL. Adverse effects associated with long-term administration of azole antifungal agents. <i>Drugs</i>. 2019;79(8):833-853. doi:10.1007/s40265-019-01127-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/31093949/pubmed" id="31093949" target="_blank">31093949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27430151">
<a name="27430151"></a>Benjamin Lash D, Jolliff J, Munoz A, Heidari A. Cross-reactivity between voriconazole, fluconazole and itraconazole. <i>J Clin Pharm Ther</i>. 2016;41(5):566-567. doi:10.1111/jcpt.12417<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/27430151/pubmed" id="27430151" target="_blank">27430151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26881962">
<a name="26881962"></a>Berens P, Eglash A, Malloy M, Steube AM. ABM clinical protocol #26: persistent pain with breastfeeding. <i>Breastfeed Med.</i> 2016;11(2):46-53. doi:10.1089/bfm.2016.29002.pjb<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/26881962/pubmed" id="26881962" target="_blank">26881962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16311263">
<a name="16311263"></a>Bergner R, Hoffmann M, Riedel KD, et al. Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg. <i>Nephrol Dial Transplant</i>. 2006;21(4):1019-1023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/16311263/pubmed" id="16311263" target="_blank">16311263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7579091">
<a name="7579091"></a>Berl T, Wilner KD, Gardner M, et al. Pharmacokinetics of fluconazole in renal failure. <i>J Am Soc Nephrol</i>. 1995;6(2):242-247.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/7579091/pubmed" id="7579091" target="_blank">7579091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Blair.1">
<a name="Blair.1"></a>Blair JE, Ampel NM. Coccidioidal meningitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9429366">
<a name="9429366"></a>Bodley V, Powers D. Long-term treatment of a breastfeeding mother with fluconazole-resolved nipple pain caused by yeast: a case study. <i>J Hum Lact.</i>1997;13(4):307-311. doi:10.1177/089033449701300416<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/9429366/pubmed" id="9429366" target="_blank">9429366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Microbial Therapy</i>. 27th ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.2">
<a name="Bradley.2"></a>Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 28th ed. American Academy of Pediatrics; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradsher.2018">
<a name="Bradsher.2018"></a>Bradsher RW. Treatment of blastomycosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 21, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2184510">
<a name="2184510"></a>Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. <i>Rev Infect Dis</i>. 1990;12(suppl 3):S318-S326. doi:10.1093/clinids/12.supplement_3.s318<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/2184510/pubmed" id="2184510" target="_blank">2184510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al; American Society of Health-System Pharmacists; Infectious Diseases Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm.</i> 2013;70(3):195-283. doi: 10.2146/ajhp120568.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11583049">
<a name="11583049"></a>Brent NB. Thrush in the breastfeeding dyad: results of a survey on diagnosis and treatment. <i>Clin Pediatr (Phila)</i>. 2001;40(9):503-506. doi: 10.1177/000992280104000905.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/11583049/pubmed" id="11583049" target="_blank">11583049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brodell.2018">
<a name="Brodell.2018"></a>Brodell RT, Dolohanty LB. Intertrigo. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33383164">
<a name="33383164"></a>Budani MC, Fensore S, Di Marzio M, Tiboni GM. Maternal use of fluconazole and congenital malformations in the progeny: a meta-analysis of the literature. <i>Reprod Toxicol.</i> 2021;100:42-51. doi:10.1016/j.reprotox.2020.12.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/33383164/pubmed" id="33383164" target="_blank">33383164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>Candidiasis (Mucocutaneous). In: US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf</a>. Updated May 26, 2020. Accessed June 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19357635">
<a name="19357635"></a>Centers for Disease Control and Prevention (CDC). Guidelines for Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Adults and Adolescents. Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America. <i>MMWR Recomm Rep.</i> 2009;58(RR-4):1-207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/19357635/pubmed" id="19357635" target="_blank">19357635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19499872">
<a name="19499872"></a>Chakravarty C, Singh PM, Trikha A, Arora MK. Fluconazole-induced recurrent ventricular fibrillation leading to multiple cardiac arrests. <i>Anaesth Intensive Care</i>. 2009;37(3):477-480. doi:10.1177/0310057X0903700311<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/19499872/pubmed" id="19499872" target="_blank">19499872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18462107">
<a name="18462107"></a>Chapman SW, Dismukes WE, Proia LA, et al; Infectious Diseases Society of America. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. <i>Clin Infect Dis. </i>2008;46(12):1801-1812.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/18462107/pubmed" id="18462107" target="_blank">18462107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15181494">
<a name="15181494"></a>Chen CM, Ho MW, Yu WL, Wang JH. Fungal peritonitis in peritoneal dialysis patients: effect of fluconazole treatment and use of the twin-bag disconnect system. <i>J Microbiol Immunol Infect.</i> 2004;37(2):115-120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/15181494/pubmed" id="15181494" target="_blank">15181494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23697747">
<a name="23697747"></a>Chen SC, Korman TM, Slavin MA, et al; Australia and New Zealand Mycoses Interest Group (ANZMIG) Cryptococcus Study. Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii. <i>Clin Infect Dis</i>. 2013;57(4):543-551. doi: 10.1093/cid/cit341.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/23697747/pubmed" id="23697747" target="_blank">23697747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34250196">
<a name="34250196"></a>Cheng JH, Yip CW, Jiang YK, et al. Clinical predictors impacting cryptococcal dissemination and poor outcome in patients with cirrhosis. <i>Open Forum Infect Dis.</i> 2021;8(7):ofab296. doi:10.1093/ofid/ofab296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/34250196/pubmed" id="34250196" target="_blank">34250196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12033079">
<a name="12033079"></a>Chetwynd EM, Ives TJ, Payne PM, Edens-Bartholomew N. Fluconazole for postpartum candidal mastitis and infant thrush. <i>J Hum Lact. </i>2002;18(2):168-171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/12033079/pubmed" id="12033079" target="_blank">12033079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9324192">
<a name="9324192"></a>Cohen LG, DiBiasio A, Lisco SJ, Hurford WE. Fluconazole serum concentrations and pharmacokinetics in an obese patient. <i>Pharmacotherapy</i>. 1997;17(5):1023-1026.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/9324192/pubmed" id="9324192" target="_blank">9324192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1990982">
<a name="1990982"></a>Coldiron BM, Manders SM. Persistent Candida intertrigo treated with fluconazole. <i>Arch Dermatol.</i> 1991;127(2):165-166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/1990982/pubmed" id="1990982" target="_blank">1990982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Como.1">
<a name="Como.1"></a>Como JA, Dismukes WE. Oral Azole Drugs as Systemic Antifungal Therapy. <i>N Engl J Med</i>. 1993;330(4):263-272.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14551347">
<a name="14551347"></a>Cousin L, Berre ML, Launay-Vacher V, Izzedine H, Deray G. Dosing guidelines for fluconazole in patients with renal failure. <i>Nephrol Dial Transplant.</i> 2003;18(11):2227-2231.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/14551347/pubmed" id="14551347" target="_blank">14551347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cox.2018a">
<a name="Cox.2018a"></a>Cox GM, Perfect JR. Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 18, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cox.2018b">
<a name="Cox.2018b"></a>Cox GM, Perfect JR. Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in patients without HIV. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 18, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cox.2018c">
<a name="Cox.2018c"></a>Cox GM, Perfect JR. Cryptococcus neoformans infection outside the central nervous system. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 21, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19548943">
<a name="19548943"></a>Craythorne E, Creamer D. Stevens-Johnson syndrome due to prophylactic fluconazole in two patients with liver failure. <i>Clin Exp Dermatol</i>. 2009;34(7):e389-e390. doi:10.1111/j.1365-2230.2009.03365.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/19548943/pubmed" id="19548943" target="_blank">19548943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30535104">
<a name="30535104"></a>Davis MR, Nguyen MH, Donnelley MA, Thompson Iii GR. Tolerability of long-term fluconazole therapy. <i>J Antimicrob Chemother</i>. 2019;74(3):768-771. doi:10.1093/jac/dky501<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/30535104/pubmed" id="30535104" target="_blank">30535104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8448970">
<a name="8448970"></a>Debruyne D, Ryckelynck JP. Clinical pharmacokinetics of fluconazole. <i>Clin Pharmacokinet.</i> 1993;24(1):10-27. doi:10.2165/00003088-199324010-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/8448970/pubmed" id="8448970" target="_blank">8448970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29294202">
<a name="29294202"></a>Demir S, Cetin EA, Unal D, et al. Generalized fixed drug eruption induced by fluconazole without cross-reactivity to itraconazole: lymphocyte transformation test confirms the diagnosis. <i>Drug Saf Case Rep</i>. 2018;5(1):2. doi:10.1007/s40800-017-0067-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/29294202/pubmed" id="29294202" target="_blank">29294202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18627382">
<a name="18627382"></a>Di Leo E, Nettis E, Priore MG, Ferrannini A, Vacca A. Maculopapular rash due to fluconazole. <i>Clin Exp Dermatol</i>. 2009;34(3):404. doi:10.1111/j.1365-2230.2008.02895.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/18627382/pubmed" id="18627382" target="_blank">18627382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25814733">
<a name="25814733"></a>Di Lernia V, Ricci C. Fluconazole-induced acute generalized exanthematous pustulosis. <i>Indian J Dermatol</i>. 2015;60(2):212. doi:10.4103/0019-5154.152572<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/25814733/pubmed" id="25814733" target="_blank">25814733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Diflucan.2020.09">
<a name="Diflucan.2020.09"></a>Diflucan (fluconazole) oral suspension, tablets [prescribing information]. New York, NY: Roerig, Division of Pfizer Inc; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Diflucan.1">
<a name="Diflucan.1"></a>Diflucan (fluconazole in Dextrose injection and fluconazole in Sodium Chloride injection) [prescribing information]. New York, NY: Pfizer; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34269140">
<a name="34269140"></a>Douglas P. Overdiagnosis and overtreatment of nipple and breast candidiasis: a review of the relationship between diagnoses of mammary candidiasis and <i>Candida albicans</i> in breastfeeding women. <i>Womens Health (Lond).</i> 2021;17:17455065211031480. doi:10.1177/17455065211031480<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/34269140/pubmed" id="34269140" target="_blank">34269140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9631990">
<a name="9631990"></a>Drake L, Babel D, Stewart DM, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. <i>J Am Acad Dermatol</i>. 1998;38(6, pt 2):S87-S94. doi:10.1016/s0190-9622(98)70491-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/9631990/pubmed" id="9631990" target="_blank">9631990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8970221">
<a name="8970221"></a>Driessen M, Ellis JB, Cooper PA, et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. <i>Pediatr Infect Dis J</i>. 1996;15(12):1107-1112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/8970221/pubmed" id="8970221" target="_blank">8970221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9476509">
<a name="9476509"></a>Duswald KH, Penk A, Pittrow L. High-dose therapy with fluconazole &gt; or = 800 mg day-1. <i>Mycoses</i>. 1997;40(7-8):267-277. doi:10.1111/j.1439-0507.1997.tb00231.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/9476509/pubmed" id="9476509" target="_blank">9476509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23325436">
<a name="23325436"></a>Egunsola O, Adefurin A, Fakis A, Jacqz-Aigrain E, Choonara I, Sammons H. Safety of fluconazole in paediatrics: a systematic review. <i>Eur J Clin Pharmacol</i>. 2013;69(6):1211-1221.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/23325436/pubmed" id="23325436" target="_blank">23325436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fishman.2018">
<a name="Fishman.2018"></a>Fishman JA, Alexander BD. Prophylaxis of infections in solid organ transplantation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fluconazole.2">
<a name="Fluconazole.2"></a>Fluconazole injection (fluconazole in sodium chloride, IV infusion, USP) [prescribing information]. Deerfield, IL: Baxter Healthcare Corp; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fluconazole.3">
<a name="Fluconazole.3"></a>Fluconazole injection [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fluconazole.1">
<a name="Fluconazole.1"></a>Fluconazole injection [prescribing information]. Eatontown, NJ: West-Ward Pharmaceutical Corp; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17712772">
<a name="17712772"></a>Foo H, Gottlieb T. Lack of cross-hepatotoxicity between voriconazole and posaconazole. <i>Clin Infect Dis</i>. 2007;45(6):803-805. doi:10.1086/521174<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/17712772/pubmed" id="17712772" target="_blank">17712772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7761190">
<a name="7761190"></a>Force RW. Fluconazole concentrations in breast milk. <i>Pediatr Infect Dis J.</i> 1995;14(3):235-236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/7761190/pubmed" id="7761190" target="_blank">7761190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27470238">
<a name="27470238"></a>Galgiani JN, Ampel NM, Blair JE, et al. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. <i>Clin Infect Dis</i>. 2016;63(6):e112-e146. doi:10.1093/cid/ciw360<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/27470238/pubmed" id="27470238" target="_blank">27470238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14686224">
<a name="14686224"></a>Gandhi PJ, Menezes PA, Vu HT, Rivera AL, Ramaswamy K. Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient. <i>Am J Health Syst Pharm</i>. 2003;60(23):2479-2483. doi:10.1093/ajhp/60.23.2479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/14686224/pubmed" id="14686224" target="_blank">14686224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30090793">
<a name="30090793"></a>Gayam V, Khalid M, Dahal S, Garlapati P, Gill A. Hyperacute liver injury following intravenous fluconazole: a rare case of dose-independent hepatotoxicity. <i>J Family Med Prim Care</i>. 2018;7(2):451-454. doi:10.4103/jfmpc.jfmpc_330_17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/30090793/pubmed" id="30090793" target="_blank">30090793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23129968">
<a name="23129968"></a>George J, Sharma A, Dixit R, Chhabra N, Sharma S. Toxic epidermal necrolysis caused by fluconazole in a patient with human immunodeficiency virus infection. <i>J Pharmacol Pharmacother</i>. 2012;3(3):276-278. doi:10.4103/0976-500X.99445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/23129968/pubmed" id="23129968" target="_blank">23129968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23170870">
<a name="23170870"></a>Georgiadou SP, Tarrand J, Sipsas NV, Kontoyiannia DP. Candiduria in haematologic malignancy patients without a urinary catheter: nothing more than a frailty marker? <i>Mycoses</i>. 2013;56(3):311-314 doi:10.1111/myc.12024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/23170870/pubmed" id="23170870" target="_blank">23170870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27251341">
<a name="27251341"></a>Gharibian KN, Mueller BA. Fluconazole dosing predictions in critically-ill patients receiving prolonged intermittent renal replacement therapy: a Monte Carlo simulation approach. <i>Clin Nephrol</i>. 2016;86(7):43-50. doi:10.5414/CN108824<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/27251341/pubmed" id="27251341" target="_blank">27251341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16339606">
<a name="16339606"></a>Glasmacher A, Cornely O, Ullmann AJ, et al; Itraconazole Research Group of Germany. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. <i>J Antimicrob Chemother</i>. 2006;57(2):317-325.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/16339606/pubmed" id="16339606" target="_blank">16339606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glickman.2018">
<a name="Glickman.2018"></a>Glickman JD, Cox GM, Kauffman CA. Fungal peritonitis in peritoneal dialysis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16231260">
<a name="16231260"></a>Goldman M, Cloud GA, Wade KD, et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. <i>Clin Infect Dis</i>. 2005;41(10):1473-1480. doi:10.1086/497373<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/16231260/pubmed" id="16231260" target="_blank">16231260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldstein.2018">
<a name="Goldstein.2018"></a>Goldstein AO, Goldstein BG. Dermatophyte (tinea) infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 27, 2023a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldstein.2022">
<a name="Goldstein.2022"></a>Goldstein BG, Goldstein AO. Tinea versicolor (pityriasis versicolor). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 27, 2023b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32535150">
<a name="32535150"></a>Gómez-López A. Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation. <i>Clin Microbiol Infect</i>. 2020;26(11):1481-1487. doi:10.1016/j.cmi.2020.05.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/32535150/pubmed" id="32535150" target="_blank">32535150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22086858">
<a name="22086858"></a>Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. <i>J Antimicrob Chemother.</i> 2012;67(2):269-89. doi:10.1093/jac/dkr450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/22086858/pubmed" id="22086858" target="_blank">22086858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18478357">
<a name="18478357"></a>Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. <i>Mycopathologia</i>. 2008;166(5-6):353-367. doi:10.1007/s11046-008-9109-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/18478357/pubmed" id="18478357" target="_blank">18478357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19106754">
<a name="19106754"></a>Healy CM, Baker CJ. Fluconazole Prophylaxis in the Neonatal Intensive Care Unit. <i>Pediatr Infect Dis J</i>. 2009;28(1):49-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/19106754/pubmed" id="19106754" target="_blank">19106754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy.</i> 2009;29(5):562-577. doi:10.1592/phco.29.5.562<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26553194">
<a name="26553194"></a>Hoetzenecker W, Nägeli M, Mehra ET, et al. Adverse cutaneous drug eruptions: current understanding. <i>Semin Immunopathol</i>. 2016;38(1):75-86. doi:10.1007/s00281-015-0540-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/26553194/pubmed" id="26553194" target="_blank">26553194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23137136">
<a name="23137136"></a>Hope WW, Castagnola E, Groll AH, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. <i>Clin Microbiol Infect</i>. 2012;18(suppl 7):38-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/23137136/pubmed" id="23137136" target="_blank">23137136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33603574">
<a name="33603574"></a>Hornik CD, Bondi DS, Greene NM, Cober MP, John B. Review of fluconazole treatment and prophylaxis for invasive Candidiasis in neonates. <i>J Pediatr Pharmacol Ther</i>. 2021;26(2):115-122. doi:10.5863/1551-6776-26.2.115<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/33603574/pubmed" id="33603574" target="_blank">33603574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28893774">
<a name="28893774"></a>Hwang MF, Beechinor RJ, Wade KC, et al. External evaluation of two fluconazole infant population pharmacokinetic models. <i>Antimicrob Agents Chemother</i>. 2017;61(12):e01352-17. doi:10.1128/AAC.01352-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/28893774/pubmed" id="28893774" target="_blank">28893774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25263725">
<a name="25263725"></a>Islam S, Singer M, Kulhanjian JA. Toxic epidermal necrolysis in a neonate receiving fluconazole. <i>J Perinatol</i>. 2014;34(10):792-794. doi:10.1038/jp.2014.92<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/25263725/pubmed" id="25263725" target="_blank">25263725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jaroszewski.2018">
<a name="Jaroszewski.2018"></a>Jaroszewski D, Blair JE, Ampel NM. Management of pulmonary sequelae and complications of coccidioidomycosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35320642">
<a name="35320642"></a>Jarvis JN, Lawrence DS, Meya DB, et al; Ambition Study Group. Single-dose liposomal amphotericin B treatment for cryptococcal meningitis. <i>N Engl J Med</i>. 2022;386(12):1109-1120. doi:10.1056/NEJMoa2111904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/35320642/pubmed" id="35320642" target="_blank">35320642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10030772">
<a name="10030772"></a>Jick SS. Pregnancy outcomes after maternal exposure to fluconazole. <i>Pharmacotherapy. </i>1999;19(2):221-222.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/10030772/pubmed" id="10030772" target="_blank">10030772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31762485">
<a name="31762485"></a>Joseph M, Brady R, Attridge R, et al. Critically ill recipients of weight-based fluconazole meeting drug-induced liver injury network criteria. <i>Hosp Pharm</i>. 2019;54(6):378-384. doi:10.1177/0018578718802583<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/31762485/pubmed" id="31762485" target="_blank">31762485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23750489">
<a name="23750489"></a>Kao WY, Su CW, Huang YS, et al. Risk of oral antifungal agent-induced liver injury in Taiwanese. <i>Br J Clin Pharmacol</i>. 2014;77(1):180-189. doi:10.1111/bcp.12178<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/23750489/pubmed" id="23750489" target="_blank">23750489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15841655">
<a name="15841655"></a>Karakas M, Durdu M, Memişoğlu HR. Oral fluconazole in the treatment of tinea versicolor. <i>J Dermatol</i>. 2005;32(1):19-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/15841655/pubmed" id="15841655" target="_blank">15841655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kauffman.3">
<a name="Kauffman.3"></a>Kauffman CA. Esophageal candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 26, 2023a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kauffman.4">
<a name="Kauffman.4"></a>Kauffman CA. Candida infections of the abdomen and thorax. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 26, 2023b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kauffman.5">
<a name="Kauffman.5"></a>Kauffman CA. Oropharyngeal candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 26, 2023c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12495173">
<a name="12495173"></a>Khazan M, Mathis AS. Probable case of torsades de pointes induced by fluconazole. <i>Pharmacotherapy</i>. 2002;22(12):1632-1637. doi:10.1592/phco.22.17.1632.34129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/12495173/pubmed" id="12495173" target="_blank">12495173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11206042">
<a name="11206042"></a>Kishino S, Koshinami Y, Hosoi T, et al. Effective fluconazole therapy for liver transplant recipients during continuous hemodiafiltration. <i>Ther Drug Monit</i>. 2001;23(1):4-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/11206042/pubmed" id="11206042" target="_blank">11206042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24610666">
<a name="24610666"></a>Kotogyan A, Harmanyeri Y, Tahsin Gunes A, et al. Efficacy and safety of oral fluconazole in the treatment of patients with tinea corporis, cruris or pedis or cutaneous candidosis: a multicentre, open, noncomparative study. <i>Clin Drug Investig</i>. 1996;12(2):59-66. doi:10.2165/00044011-199612020-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/24610666/pubmed" id="24610666" target="_blank">24610666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31659833">
<a name="31659833"></a>Kumar S, Bhale G, Brar BK. Symmetrical drug related intertriginous and flexural exanthema (SDRIFE) induced by fluconazole: An uncommon side effect of a commonly used drug. <i>Dermatol Ther</i>. 2019;32(6):e13130. doi:10.1111/dth.13130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/31659833/pubmed" id="31659833" target="_blank">31659833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27927037">
<a name="27927037"></a>Kyriakidis I, Tragiannidis A, Munchen S, Groll AH. Clinical hepatotoxicity associated with antifungal agents. <i>Expert Opin Drug Saf</i>. 2017;16(2):149-165. doi:10.1080/14740338.2017.1270264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/27927037/pubmed" id="27927037" target="_blank">27927037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lawson.1998">
<a name="Lawson.1998"></a>Lawson C, Karlowsky JA, Zhanel GG. Fluconazole-induced hepatotoxicity: review of published case reports. <i>The Canadian Journal of Hospital Pharmacy.</i> 1998;51(2):61-63.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27184665">
<a name="27184665"></a>Lee J, Kim HS, Shin SH, et al. Efficacy and safety of fluconazole prophylaxis in extremely low birth weight infants: multicenter pre-post cohort study. <i>BMC Pediatr</i>. 2016;16:67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/27184665/pubmed" id="27184665" target="_blank">27184665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26829719">
<a name="26829719"></a>Lee JM, Graciano AL, Dabrowski L, Kuzmic B, Tablizo MA. Coccidioidomycosis in infants: A retrospective case series. <i>Pediatr Pulmonol</i>. 2016;51(8):858-862.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/26829719/pubmed" id="26829719" target="_blank">26829719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1593362">
<a name="1593362"></a>Lee JW, Seibel NL, Amantea M, et al. Safety and Pharmacokinetics of Fluconazole in Children With Neoplastic Diseases. <i>J Pediatr</i>. 1992;120(6):987-993.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/1593362/pubmed" id="1593362" target="_blank">1593362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28285752">
<a name="28285752"></a>Leonart LP, Tonin FS, Ferreira VL, Tavares da Silva Penteado S, de Araújo Motta F, Pontarolo R. Fluconazole doses used for prophylaxis of invasive fungal infection in neonatal intensive care units: a network meta-analysis. <i>J Pediatr</i>. 2017;185:129-135.e6. doi:10.1016/j.jpeds.2017.02.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/28285752/pubmed" id="28285752" target="_blank">28285752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29744900">
<a name="29744900"></a>Leroux S, Jacqz-Aigrain E, Elie V, et al. Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial. <i>Br J Clin Pharmacol</i>. 2018;84(9):1989-1999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/29744900/pubmed" id="29744900" target="_blank">29744900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27282851">
<a name="27282851"></a>Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment [published correction appears in <i>Perit Dial Int</i>. 2018;38(4):313]. <i>Perit Dial Int</i>. 2016;36(5):481-508. doi:10.3747/pdi.2016.00078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/27282851/pubmed" id="27282851" target="_blank">27282851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26597673">
<a name="26597673"></a>Lo Re V 3rd, Carbonari DM, Lewis JD, et al. Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status. <i>Am J Med</i>. 2016;129(3):283-91.e5. doi:10.1016/j.amjmed.2015.10.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/26597673/pubmed" id="26597673" target="_blank">26597673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25074285">
<a name="25074285"></a>Lopez ND, Phillips KM. Fluconazole pharmacokinetics in a morbidly obese, critically ill patient receiving continuous venovenous hemofiltration. <i>Pharmacotherapy</i>. 2014;34(9):e162-e168. doi: 0.1002/phar.1470<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/25074285/pubmed" id="25074285" target="_blank">25074285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12439793">
<a name="12439793"></a>Malani PN, McNeil SA, Bradley SF, Kauffman CA. Candida albicans sternal wound infections: a chronic and recurrent complication of median sternotomy. <i>Clin Infect Dis</i>. 2002;35(11):1316-1320.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/12439793/pubmed" id="12439793" target="_blank">12439793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14616112">
<a name="14616112"></a>Martínez-Alonso JC, Domínguez-Ortega FJ, Fuentes-Gonzalo MJ. Urticaria and angioedema due to itraconazole. <i>Allergy</i>. 2003;58(12):1317-1318. doi:10.1046/j.0105-4538.2003.00316.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/14616112/pubmed" id="14616112" target="_blank">14616112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18359968">
<a name="18359968"></a>McMahon JH, Grayson ML. Torsades de pointes in a patient receiving fluconazole for cerebral cryptococcosis. <i>Am J Health Syst Pharm</i>. 2008;65(7):619-623. doi:10.2146/ajhp070203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/18359968/pubmed" id="18359968" target="_blank">18359968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30924967">
<a name="30924967"></a>Miller R, Assi M; AST Infectious Diseases Community of Practice. Endemic fungal infections in solid organ transplant recipients-guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13553. doi:10.1111/ctr.13553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/30924967/pubmed" id="30924967" target="_blank">30924967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29539274">
<a name="29539274"></a>Molloy SF, Kanyama C, Heyderman RS, et al; ACTA Trial Study Team. Antifungal combinations for treatment of cryptococcal meningitis in Africa. <i>N Engl J Med</i>. 2018;378(11):1004-1017. doi: 10.1056/NEJMoa1710922.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/29539274/pubmed" id="29539274" target="_blank">29539274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27401564">
<a name="27401564"></a>Momper JD, Capparelli EV, Wade KC, et al. Population pharmacokinetics of fluconazole in premature infants with birth weights less than 750 grams. <i>Antimicrob Agents Chemother</i>. 2016;60(9):5539-5545.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/27401564/pubmed" id="27401564" target="_blank">27401564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18779900">
<a name="18779900"></a>Monastirli A, Pasmatzi E, Vryzaki E, Georgiou S, Tsambaos D. Fluconazole-induced Stevens-Johnson syndrome in a HIV-negative patient. <i>Acta Derm Venereol</i>. 2008;88(5):521-522. doi:10.2340/00015555-0489<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/18779900/pubmed" id="18779900" target="_blank">18779900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1562699">
<a name="1562699"></a>Montero-Gei F, Perera A. Therapy with fluconazole for tinea corporis, tinea cruris, and tinea pedis. <i>Clin Infect Dis</i>. 1992;14(suppl 1):S77-S81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/1562699/pubmed" id="1562699" target="_blank">1562699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22263374">
<a name="22263374"></a>Moorhead AM, Amir LH, O'Brien PW, Wong S. A prospective study of fluconazole treatment for breast and nipple thrush. <i>Breastfeed Rev</i>. 2011;19(3):25-29.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/22263374/pubmed" id="22263374" target="_blank">22263374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11214774">
<a name="11214774"></a>Muhl E, Martens T, Iven H, Rob P, Bruch HP. Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. <i>Eur J Clin Pharmacol</i>. 2000;56(9-10):671-678.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/11214774/pubmed" id="11214774" target="_blank">11214774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1286742">
<a name="1286742"></a>Murakami H, Katahira H, Matsushima T, et al. Agranulocytosis during treatment with fluconazole. <i>J Int Med Res</i>. 1992;20(6):492-494. doi:10.1177/030006059202000607<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/1286742/pubmed" id="1286742" target="_blank">1286742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23172357">
<a name="23172357"></a>Nakai N, Katoh N. Fixed drug eruption caused by fluconazole: a case report and mini-review of the literature. <i>Allergol Int</i>. 2013;62(1):139-141. doi:10.2332/allergolint.12-LE-0464<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/23172357/pubmed" id="23172357" target="_blank">23172357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. https://www.nice.org.uk/guidance/cg183/resources/drug-allergy-diagnosis-and-management-pdf-35109811022821. Published September 3, 2014. Accessed April 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25918080">
<a name="25918080"></a>Nenoff P, Krüger C, Paasch U, Ginter-Hanselmayer G. Mycology - an update part 3: Dermatomycoses: topical and systemic therapy. <i>J Dtsch Dermatol Ges</i>. 2015;13(5):387-410; quiz 411.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/25918080/pubmed" id="25918080" target="_blank">25918080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2059703">
<a name="2059703"></a>Neuhaus G, Pavic N, Pletscher M. Anaphylactic reaction after oral fluconazole. <i>BMJ</i>. 1991;302(6788):1341. doi:10.1136/bmj.302.6788.1341-b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/2059703/pubmed" id="2059703" target="_blank">2059703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9762826">
<a name="9762826"></a>Nozickova M, Koudelkova V, Kulikova Z, Malina L, Urbanowski S, Silney W. A comparison of the efficacy of oral fluconazole, 150 mg/week versus 50 mg/day, in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidosis. <i>Int J Dermatol.</i> 1998;37(9):703-705.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/9762826/pubmed" id="9762826" target="_blank">9762826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20038244">
<a name="20038244"></a>Nussbaum JC, Jackson A, Namarika D, et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. <i>Clin Infect Dis</i>. 2010;50(3):338-344. doi:10.1086/649861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/20038244/pubmed" id="20038244" target="_blank">20038244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31259879">
<a name="31259879"></a>Oualha M, Tréluyer JM, Moshous D, et al. Fluconazole exposure in plasma and bile during continuous venovenous hemodialysis. <i>Ther Drug Monit</i>. 2019;41(4):544-546. doi:10.1097/FTD.0000000000000641<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/31259879/pubmed" id="31259879" target="_blank">31259879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1623910">
<a name="1623910"></a>Oono S, Tabei K, Tetsuka T, Asano Y. The pharmacokinetics of fluconazole during haemodialysis in uraemic patients. <i>Eur J Clin Pharmacol</i>. 1992;42(6):667-669.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/1623910/pubmed" id="1623910" target="_blank">1623910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9332510">
<a name="9332510"></a>Pappas PG, Bradsher RW, Kauffman CA, et al; The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Treatment of blastomycosis with higher doses of fluconazole. <i>Clin Infect Dis</i>. 1997;25(2):200-205. doi:10.1086/514539<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/9332510/pubmed" id="9332510" target="_blank">9332510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19191635">
<a name="19191635"></a>Pappas PG, Kauffman CA, Andes D, et al; Infectious Diseases Society of America. Clinical practice guideline for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2009;48(5):503-535. doi:10.1086/596757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/19191635/pubmed" id="19191635" target="_blank">19191635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26679628">
<a name="26679628"></a>Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-e50. doi:10.1093/cid/civ933<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/26679628/pubmed" id="26679628" target="_blank">26679628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7625624">
<a name="7625624"></a>Pappas PG, Kauffman CA, Perfect J, et al. Alopecia associated with fluconazole therapy. <i>Ann Intern Med</i>. 1995;123(5):354-357. doi:10.7326/0003-4819-123-5-199509010-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/7625624/pubmed" id="7625624" target="_blank">7625624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31689712">
<a name="31689712"></a>Pastick KA, Nalintya E, Tugume L, et al. Cryptococcosis in pregnancy and the postpartum period: Case series and systematic review with recommendations for management. <i>Med Mycol</i>. 2020;58(3):282‐292. doi:10.1093/mmy/myz084<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/31689712/pubmed" id="31689712" target="_blank">31689712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21930888">
<a name="21930888"></a>Patel K, Roberts JA, Lipman J, Tett SE, Deldot ME, Kirkpatrick CM. Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets. <i>Antimicrob Agents Chemother</i>. 2011;55(12):5868-5873. doi:10.1128/AAC.00424-11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/21930888/pubmed" id="21930888" target="_blank">21930888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20047480">
<a name="20047480"></a>Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of Cryptococcal disease: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2010;50(3):291-322. doi:10.1086/649858<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/20047480/pubmed" id="20047480" target="_blank">20047480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16849620">
<a name="16849620"></a>Pham CP, de Feiter PW, van der Kuy PH, van Mook WN. Long QTc interval and torsade de pointes caused by fluconazole. <i>Ann Pharmacother</i>. 2006;40(7-8):1456-1461. doi:10.1345/aph.1G741<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/16849620/pubmed" id="16849620" target="_blank">16849620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19164151">
<a name="19164151"></a>Pinto A, Chan RC. Lack of allergic cross-reactivity between fluconazole and voriconazole. <i>Antimicrob Agents Chemother</i>. 2009;53(4):1715-1716. doi:10.1128/AAC.01500-08<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/19164151/pubmed" id="19164151" target="_blank">19164151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21085048">
<a name="21085048"></a>Piper L, Smith PB, Hornik CP, et al. Fluconazole Loading Dose Pharmacokinetics and Safety in Infants. <i>Pediatr Infect Dis J</i>. 2011;30(5):375-378.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/21085048/pubmed" id="21085048" target="_blank">21085048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20297862">
<a name="20297862"></a>Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. <i>Drug Saf</i>. 2010;33(4):303-314. doi:10.2165/11531850-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/20297862/pubmed" id="20297862" target="_blank">20297862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30417394">
<a name="30417394"></a>Quint T, Wöhrl S, Kinaciyan T. Fixed drug eruption caused by fluconazole-An underdiagnosed but recurrent problem. <i>Contact Dermatitis</i>. 2019;80(3):172-173. doi:10.1111/cod.13149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/30417394/pubmed" id="30417394" target="_blank">30417394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20634438">
<a name="20634438"></a>Restrepo C, Chacon J, Manjarres G. Fungal peritonitis in peritoneal dialysis patients: successful prophylaxis with fluconazole as demonstrated by prospective randomized control trial. <i>Perit Dial Int.</i> 2010;30(6):619-625. doi:10.3747/pdi.2008.00189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/20634438/pubmed" id="20634438" target="_blank">20634438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7935701">
<a name="7935701"></a>Rex JH, Bennett JE, Sugar AM; Candidemia Study Group and the National Institute. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. <i>N Engl J Med. </i>1994;331(20):1325-1330. doi:10.1056/NEJM199411173312001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/7935701/pubmed" id="7935701" target="_blank">7935701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12746765">
<a name="12746765"></a>Rex JH, Pappas PG, Karchmer AW, et al; National Institute of Allergy and Infectious Diseases Mycoses Study Group. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. <i>Clin Infect Dis</i>. 2003;36(10):1221-1228.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/12746765/pubmed" id="12746765" target="_blank">12746765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rikken.1">
<a name="Rikken.1"></a>Rikken B, Hartwig NG, van den Hoek J. Renal candida infection in infants and neonates: report of four cases, review of the literature and treatment proposal. <i>Curr Urol</i>. 2007;1:113-120. doi:10.1159/000115292</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7592177">
<a name="7592177"></a>Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M. Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis. <i>J Antimicrob Chemother.</i> 1995;35(5):641-647. doi:10.1093/jac/35.5.641<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/7592177/pubmed" id="7592177" target="_blank">7592177</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29644223">
<a name="29644223"></a>Salem M, Reichlin T, Fasel D, Leuppi-Taegtmeyer A. Torsade de pointes and systemic azole antifungal agents: analysis of global spontaneous safety reports. <i>Glob Cardiol Sci Pract</i>. 2017;2017(2):11. doi:10.21542/gcsp.2017.11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/29644223/pubmed" id="29644223" target="_blank">29644223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9631989">
<a name="9631989"></a>Scher RK, Breneman D, Rich P, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. <i>J Am Acad Dermatol</i>. 1998;38(6, pt 2):S77-S86. doi:10.1016/s0190-9622(98)70490-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/9631989/pubmed" id="9631989" target="_blank">9631989</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Schilling CG, Seay RE, Larson TA, Meier KR. Excretion of fluconazole inhuman breast milk [abstract]. <i>Pharmacotherapy</i>. 1993;13(3):287.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30829805">
<a name="30829805"></a>Schneller-Pavelescu L, Ochando-Ibernón G, Vergara-de Caso E, Silvestre-Salvador JF. Herpes simplex-like fixed drug eruption induced by fluconazole without cross-reactivity to itraconazole. <i>Dermatitis</i>. 2019;30(2):174-175. doi:10.1097/DER.0000000000000451<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/30829805/pubmed" id="30829805" target="_blank">30829805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24424789">
<a name="24424789"></a>Science M, Robinson PD, MacDonald T, Rassekh SR, Dupuis LL, Sung L. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. <i>Pediatr Blood Cancer</i>. 2014;61(3):393-400. doi:10.1002/pbc.24847<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/24424789/pubmed" id="24424789" target="_blank">24424789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23879279">
<a name="23879279"></a>Sedlak T, Shufelt C, Iribarren C, Lyon LL, Bairey Merz CN. Oral contraceptive use and the ECG: evidence of an adverse QT effect on corrected QT interval. <i>Ann Noninvasive Electrocardiol.</i> 2013;18(4):389-398. doi:10.1111/anec.12050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/23879279/pubmed" id="23879279" target="_blank">23879279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23465015">
<a name="23465015"></a>Silveira FP, Kusne S; AST Infectious Diseases Community of Practice. Candida infections in solid organ transplantation. <i>Am J Transplant</i>. 2013;13(suppl 4):220-227. doi:10.1111/ajt.12114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/23465015/pubmed" id="23465015" target="_blank">23465015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26938747">
<a name="26938747"></a>Singh Mahal H. Fluconazole-induced type 1 kounis syndrome. <i>Am J Ther</i>. 2016;23(3):e961-e962. doi:10.1097/MJT.0000000000000113<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/26938747/pubmed" id="26938747" target="_blank">26938747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22694672">
<a name="22694672"></a>Singh N, Huprikar S, Burdette SD, Morris MI, Blair JE, Wheat LJ; American Society of Transplantation, Infectious Diseases Community of Practice, Donor-Derived Fungal Infection Working Group. Donor-derived fungal infections in organ transplant recipients: guidelines of the American Society of Transplantation, Infectious Diseases Community of Practice. <i>Am J Transplant</i>. 2012;12(9):2414-2428.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/22694672/pubmed" id="22694672" target="_blank">22694672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25806406">
<a name="25806406"></a>Singh N, Sifri CD, Silveira FP, et al. Cryptococcosis in patients with cirrhosis of the liver and posttransplant outcomes.<i> Transplantation</i>. 2015;99(10):2132-2141. doi:10.1097/TP.0000000000000690<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/25806406/pubmed" id="25806406" target="_blank">25806406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25455854">
<a name="25455854"></a>Sinnollareddy MG, Roberts MS, Lipman J, Robertson TA, Peake SL, Roberts JA. Pharmacokinetics of fluconazole in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration. <i>Int J Antimicrob Agents</i>. 2015;45(2):192-195. doi:10.1016/j.ijantimicag.2014.08.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/25455854/pubmed" id="25455854" target="_blank">25455854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15329425">
<a name="15329425"></a>Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.<i> N Engl J Med</i>. 2004;351(9):876-883. doi:10.1056/NEJMoa033114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/15329425/pubmed" id="15329425" target="_blank">15329425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15751740">
<a name="15751740"></a>Song JC, Deresinski S. Hepatotoxicity of antifungal agents. <i>Curr Opin Investig Drugs</i>. 2005;6(2):170-177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/15751740/pubmed" id="15751740" target="_blank">15751740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12684933">
<a name="12684933"></a>Spellberg B, Rieg G, Bayer A, Edwards JE Jr. Lack of cross-hepatotoxicity between fluconazole and voriconazole. <i>Clin Infect Dis</i>. 2003;36(8):1091-1093. doi:10.1086/374255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/12684933/pubmed" id="12684933" target="_blank">12684933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30544724">
<a name="30544724"></a>Spernovasilis N, Kofteridis DP. Pre-existing liver disease and toxicity of antifungals. <i>J Fungi (Basel)</i>. 2018;4(4):133. doi:10.3390/jof4040133<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/30544724/pubmed" id="30544724" target="_blank">30544724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9568414">
<a name="9568414"></a>Stary A, Sarnow E. Fluconazole in the treatment of tinea corporis and tinea cruris. <i>Dermatology</i>. 1998;196(2):237-241. doi: 10.1159/000017881.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/9568414/pubmed" id="9568414" target="_blank">9568414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8002145">
<a name="8002145"></a>Stengel F, Robles-Soto M, Galimberti R, Suchil P. Fluconazole versus ketoconazole in the treatment of dermatophytoses and cutaneous candidiasis. <i>Int J Dermatol. </i>1994;33(10):726-729.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/8002145/pubmed" id="8002145" target="_blank">8002145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14616149">
<a name="14616149"></a>Su FW, Perumalswami P, Grammer LC. Acute hepatitis and rash to fluconazole. <i>Allergy</i>. 2003;58(11):1215-1216. doi:10.1046/j.0105-4538.2003.00318.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/14616149/pubmed" id="14616149" target="_blank">14616149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11346073">
<a name="11346073"></a>Takahashi T, Hitani A, Yamada H, Nakamura T, Iwamoto A. Desenitization to fluconazole in an AIDS patient. <i>Ann Pharmacother</i>. 2001;35(5):642-643. doi:10.1345/aph.10285<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/11346073/pubmed" id="11346073" target="_blank">11346073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30179565">
<a name="30179565"></a>Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update [published online ahead of print September 4, 2018]. <i>J Clin Oncol</i>. doi:10.1200/JCO.18.00374<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/30179565/pubmed" id="30179565" target="_blank">30179565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11302406">
<a name="11302406"></a>Tholakanahalli VN, Potti A, Hanley JF, Merliss AD. Fluconazole-induced torsade de pointes. <i>Ann Pharmacother</i>. 2001;35(4):432-434. doi:10.1345/aph.10210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/11302406/pubmed" id="11302406" target="_blank">11302406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30455235">
<a name="30455235"></a>Thompson GR 3rd, Krois CR, Affolter VK, et al. Examination of fluconazole-induced alopecia in an animal model and human cohort. <i>Antimicrob Agents Chemother</i>. 2019;63(2):e01384-18. doi:10.1128/AAC.01384-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/30455235/pubmed" id="30455235" target="_blank">30455235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27212965">
<a name="27212965"></a>Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. <i>Can Pharm J (Ott)</i>. 2016;149(3):139-152. doi:10.1177/1715163516641136<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/27212965/pubmed" id="27212965" target="_blank">27212965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747629">
<a name="19747629"></a>Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National Marrow Donor Program; American Society of Blood and Marrow Transplantation; et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238. doi:10.1016/j.bbmt.2009.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/19747629/pubmed" id="19747629" target="_blank">19747629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2306414">
<a name="2306414"></a>Toon S, Ross CE, Gokal R, Rowland M. An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. <i>Br J Clin Pharmacol</i>. 1990;29(2):221-226.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/2306414/pubmed" id="2306414" target="_blank">2306414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. <i>Clin Infect Dis.</i> 2005;41(8):1159-1166. doi:10.1086/444500<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. <i>Clin Infect Dis</i>. 2017;64(6):e34-e65. doi:10.1093/cid/ciw861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27275514">
<a name="27275514"></a>Tverdek FP, Kofteridis D, Kontoyiannis DP. Antifungal agents and liver toxicity: a complex interaction. <i>Expert Rev Anti Infect Ther</i>. 2016;14(8):765-776. doi:10.1080/14787210.2016.1199272<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/27275514/pubmed" id="27275514" target="_blank">27275514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.4">
<a name="HHS.4"></a>US Department of Health and Human Services (HHS); Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America and the Pediatric Infectious Diseases Society. July 2018. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/OI_Guidelines_Pediatrics.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/OI_Guidelines_Pediatrics.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. Department of Health and Human Services. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new</a>. Updated January 23, 2020. Accessed April 19, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.7">
<a name="HHS.7"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections</a>. May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.5">
<a name="HHS.5"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections</a>. Accessed April 30, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.8">
<a name="HHS.8"></a>US Department of Health and Human Services (HHS) Panel Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf.%20" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf.</a> Updated June 14, 2023. Accessed June 28, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9421318">
<a name="9421318"></a>Valtonen M, Tiula E, Neuvonen PJ. Effect of continuous venovenous haemofiltration and haemodiafiltration on the elimination of fluconazole in patients with acute renal failure. <i>J Antimicrob Chemother.</i> 1997;40(5):695-700.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/9421318/pubmed" id="9421318" target="_blank">9421318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34683388">
<a name="34683388"></a>Van Daele R, Wauters J, Lagrou K, et al. Pharmacokinetic variability and target attainment of fluconazole in critically ill patients. <i>Microorganisms</i>. 2021;9(10):2068. doi:10.3390/microorganisms9102068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/34683388/pubmed" id="34683388" target="_blank">34683388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25148892">
<a name="25148892"></a>van der Elst KC, Pereboom M, van den Heuvel ER, Kosterink JG, Schölvinck EH, Alffenaar JW. Insufficient fluconazole exposure in pediatric cancer patients and the need for therapeutic drug monitoring in critically ill children. <i>Clin Infect Dis</i>. 2014;59(11):1527-1533. doi:10.1093/cid/ciu657<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/25148892/pubmed" id="25148892" target="_blank">25148892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11570140">
<a name="11570140"></a>Vas S, Oreopoulos DG. Infections in patients undergoing peritoneal dialysis. <i>Infect Dis Clin North Am</i>. 2001;15(3):743-774.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/11570140/pubmed" id="11570140" target="_blank">11570140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34310505">
<a name="34310505"></a>Vaughn J, Tablizo MA, Zayed Z, Hepple RR, McCarty JM, Naeem F. Neonatal coccidioidomycosis: a single-center experience and review of the literature. <i>Pediatr Infect Dis J</i>. 2022;41(2):151-155. doi:10.1097/INF.0000000000003281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/34310505/pubmed" id="34310505" target="_blank">34310505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vazquez.1">
<a name="Vazquez.1"></a>Vazquez JA. Management of candidemia and invasive candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37080658">
<a name="37080658"></a>Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. <i>J Heart Lung Transplant</i>. 2023;42(5):e1-e141. doi:10.1016/j.healun.2022.10.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/37080658/pubmed" id="37080658" target="_blank">37080658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14969569">
<a name="14969569"></a>Veltri MA, Neu AM, Fivush BA, Parekh RS, Furth SL. Drug dosing during intermittent hemodialysis and continuous renal replacement therapy: special considerations in pediatric patients. <i>Paediatr Drugs.</i> 2004;6(1):45-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/14969569/pubmed" id="14969569" target="_blank">14969569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vivjoa.1">
<a name="Vivjoa.1"></a>Vivjoa (oteseconazole) [prescribing information]. Durham, NC: Mycovia Pharmaceuticals Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35895879">
<a name="35895879"></a>Vo A, Holmen J, Singh P. Neonatal coccidioidomycosis: a case report. <i>Pediatr Infect Dis J</i>. 2022;41(10):e450. doi:10.1097/INF.0000000000003646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/35895879/pubmed" id="35895879" target="_blank">35895879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19593252">
<a name="19593252"></a>Wade KC, Benjamin DK Jr, Kaufman DA, et al. Fluconazole Dosing for the Prevention or Treatment of Invasive Candidiasis in Young Infants. <i>Pediatr Infect Dis J</i>. 2009;28(8):717-723.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/19593252/pubmed" id="19593252" target="_blank">19593252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11096043">
<a name="11096043"></a>Wang AY, Yu AW, Li PK, Leung CB, Lai KN, Lui SE. Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9-year experience of fungal peritonitis in a single center. <i>Am J Kidney Dis</i>. 2000;36(6):1183-1192. doi:10.1053/ajkd.2000.19833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/11096043/pubmed" id="11096043" target="_blank">11096043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20308378">
<a name="20308378"></a>Wang JL, Chang CH, Young-Xu Y, Chan KA. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. <i>Antimicrob Agents Chemother</i>. 2010;54(6):2409-2419. doi:10.1128/AAC.01657-09<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/20308378/pubmed" id="20308378" target="_blank">20308378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al. Consensus guideline for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012. <i>Peritoneal Dialysis International</i>. 2012;32:s32-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10577320">
<a name="10577320"></a>Wassmann S, Nickenig G, Bohm M. Long QT syndrome and torsade de pointes in a patient receiving fluconazole. <i>Ann Inter Med.</i> 1999;131(10):797.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/10577320/pubmed" id="10577320" target="_blank">10577320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22627870">
<a name="22627870"></a>Watt KM, Benjamin DK Jr, Cheifetz IM, et al. Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation. <i>Pediatr Infect Dis J</i>. 2012;31(10):1042-1047.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/22627870/pubmed" id="22627870" target="_blank">22627870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30033691">
<a name="30033691"></a>Watt KM, Cohen-Wolkowiez M, Barrett JS, et al. Physiologically based pharmacokinetic approach to determine dosing on extracorporeal life support: fluconazole in children on ECMO. <i>CPT Pharmacometrics Syst Pharmacol</i>. 2018;7(10):629-637. doi:10.1002/psp4.12338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/30033691/pubmed" id="30033691" target="_blank">30033691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25896706">
<a name="25896706"></a>Watt KM, Gonzalez D, Benjamin DK Jr, et al. Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation. <i>Antimicrob Agents Chemother</i>. 2015;59(7):3935-3943. doi:10.1128/AAC.00102-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/25896706/pubmed" id="25896706" target="_blank">25896706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17806045">
<a name="17806045"></a>Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2007;45(7):807-825.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/17806045/pubmed" id="17806045" target="_blank">17806045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wingard.2018">
<a name="Wingard.2018"></a>Wingard JR. Prophylaxis of invasive fungal infection in adults with hematologic malignancies. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12352887">
<a name="12352887"></a>Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. <i>Transplantation</i>. 2002;74(5):688-695. doi: 10.1097/01.TP.0000019727.88291.F5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/12352887/pubmed" id="12352887" target="_blank">12352887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9385491">
<a name="9385491"></a>Wong SF, Leung MP, Chan MY. Pharmacokinetics of fluconazole in children requiring peritoneal dialysis. <i>Clin Ther</i>. 1997;19(5):1039-1047. doi:10.1016/s0149-2918(97)80056-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/9385491/pubmed" id="9385491" target="_blank">9385491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. http://www.who.int/maternal_child_adolescent/documents/55732/en/. Published 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. https://www.who.int/publications/i/item/9789240052178. Published June 27, 2022. Accessed October 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al; Centers for Disease Control and Prevention (CDC). Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26042815">
<a name="26042815"></a>Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/26042815/pubmed" id="26042815" target="_blank">26042815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23229485">
<a name="23229485"></a>Zeuli JD, Wilson JW, Estes LL. Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients. <i>Antimicrob Agents Chemother</i>. 2013;57(3):1121-1127. doi:10.1128/AAC.00958-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluconazole-pediatric-drug-information/abstract-text/23229485/pubmed" id="23229485" target="_blank">23229485</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13303 Version 709.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
